Role of retinoids, rexinoids and thyroid hormone in the expression of cytochrome P450 enzymes

Current Drug Metabolism

Volumn 12, Issue 2, 2011, Pages 71-88

  Brtko, Julius ^a   Dvorak, Zdenek ^b  

^a INSTITUTE OF EXPERIMENTAL ENDOCRINOLOGY   (Slovakia)

^b PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

Cytochrome P450; Hormonal regulation; Nuclear receptors; Retinoids; Thyroid hormone

Indexed keywords

AROMATIC HYDROCARBON RECEPTOR; CONSTITUTIVE ANDROSTANE RECEPTOR; CYTOCHROME P450; CYTOCHROME P450 2A; CYTOCHROME P450 2B6; CYTOCHROME P450 2C; CYTOCHROME P450 3A; ISOPRENOID; PREGNANE X RECEPTOR; RETINOIC ACID; RETINOIC ACID RECEPTOR; RETINOID; RETINOID X RECEPTOR; REXINOID DERIVATIVE; THYROID HORMONE; THYROID HORMONE RECEPTOR; THYROXINE; UNCLASSIFIED DRUG; XENOBIOTIC AGENT;

ARTICLE; BROWN ADIPOSE TISSUE; DRUG BINDING; DRUG METABOLISM; DRUG SYNTHESIS; DRUG TRANSFORMATION; ENVIRONMENTAL FACTOR; ENZYME INHIBITION; ENZYME REGULATION; GENETIC POLYMORPHISM; GLUCURONIDATION; HOMEOSTASIS; HUMAN; LIVER FUNCTION; METHYLATION; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; THYROID HORMONE RESISTANCE; WHITE ADIPOSE TISSUE;

ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; METABOLIC DETOXICATION, DRUG; MODELS, BIOLOGICAL; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, RETINOIC ACID; RECEPTORS, THYROID HORMONE; RETINOID X RECEPTORS; RETINOIDS; SIGNAL TRANSDUCTION; THYROID HORMONES;

EID: 79952781464     PISSN: 13892002     EISSN: None     Source Type: Journal    
DOI: 10.2174/138920011795016881     Document Type: Article

References (350)

1. Bushue, N.; Wan, Y.J. Retinoid pathway and cancer therapeutics. Adv. Drug Deliv. Rev., 2010, 62(13), 1285-1298.
2. Allen, J.G.; Bloxham, D.P. The pharmacology and pharmacokinetics of the retinoids. Pharmacol. Ther., 1989, 40(1), 1-27. (Pubitemid 19007320)
3. Napoli, J.L. Biosynthesis and metabolism of retinoic acid: Roles of CRBP and CRABP in retinoic acid: Roles of CRBP and CRABP in retinoic acid homeostasis. J. Nutr., 1993, 123(2 Suppl), 362-366. (Pubitemid 23073252)
4. Napoli, J.L. Retinoic acid: Its biosynthesis and metabolism. Prog. Nucleic Acid Res. Mol. Biol., 1999, 63, 139-188.
5. Chambon, P. A decade of molecular biology of retinoic acid receptors. Faseb. J., 1996, 10(9), 940-954. (Pubitemid 26285969)
6. Sun, S.Y.; Lotan, R. Retinoids and their receptors in cancer development and chemoprevention. Crit. Rev. Oncol. Hematol., 2002, 41(1), 41-55. (Pubitemid 34051581)
7. Mukherjee, R.; Davies, P.J.; Crombie, D.L.; Bischoff, E.D.; Cesario, R.M.; Jow, L.; Hamann, L.G.; Boehm, M.F.; Mondon, C.E.; Nadzan, A.M.; Paterniti, J.R., Jr.; Heyman, R.A. Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists. Nature, 1997, 386(6623), 407-410. (Pubitemid 27154482)
8. Brtko, J.; Thalhamer, J. Renaissance of the biologically active vitamin A derivatives: Established and novel directed therapies for cancer and chemoprevention. Curr. Pharm. Des., 2003, 9(25), 2067-2077. (Pubitemid 37139084)
9. Robbins, J. Factors altering thyroid hormone metabolism. Environ. Health Perspect., 1981, 38, 65-70. (Pubitemid 11036371)
10. Kohrle, J. The deiodinase family: Selenoenzymes regulating thyroid hormone availability and action. Cell Mol. Life Sci., 2000, 57(13-14), 1853-1863. (Pubitemid 32102581)
11. Mangelsdorf, D.J.; Thummel, C.; Beato, M.; Herrlich, P.; Schutz, G.; Umesono, K.; Blumberg, B.; Kastner, P.; Mark, M.; Chambon, P.; Evans, R.M. The nuclear receptor superfamily: The second decade. Cell, 1995, 83(6), 835-839.
12. Aranda, A.; Pascual, A. Nuclear hormone receptors and gene expression. Physiol. Rev., 2001, 81(3), 1269-1304. (Pubitemid 32606670)
13. Minucci, S.; Leid, M.; Toyama, R.; Saint-Jeannet, J.P.; Peterson, V.J.; Horn, V.; Ishmael, J.E.; Bhattacharyya, N.; Dey, A.; Dawid, I.B.; Ozato, K. Retinoid X receptor (RXR) within the RXR-retinoic acid receptor heterodimer binds its ligand and enhances retinoiddependent gene expression. Mol. Cell Biol., 1997, 17(2), 644-655. (Pubitemid 27044364)
14. Crowe, D.L. Receptor selective synthetic retinoids as potential cancer chemotherapy agents. Curr. Cancer Drug Targets, 2002, 2(1), 77-86. (Pubitemid 34627380)
15. Germain, P.; Staels, B.; Dacquet, C.; Spedding, M.; Laudet, V. Overview of nomenclature of nuclear receptors. Pharmacol. Rev., 2006, 58(4), 685-704. (Pubitemid 44833739)
16. Freedman, L.P. Increasing the complexity of coactivation in nuclear receptor signaling. Cell, 1999, 97(1), 5-8. (Pubitemid 29165883)
17. Privalsky, M.L. Regulation of SMRT and N-CoR corepressor function. Curr. Top Microbiol. Immunol., 2001, 254, 117-136.
18. Perissi, V.; Rosenfeld, M.G. Controlling nuclear receptors: The circular logic of cofactor cycles. Nat. Rev. Mol. Cell Biol., 2005, 6(7), 542-554. (Pubitemid 40943045)
19. Brtko, J. Retinoids, rexinoids and their cognate nuclear receptors: Character and their role in chemoprevention of selected malignant diseases. Biomed. Pap. Med. Fac. Univ. Palacky. Olomouc. Czech Repub., 2007, 151(2), 187-194.
20. Glass, C.K.; Holloway, J.M. Regulation of gene expression by the thyroid hormone receptor. Biochim. Biophys. Acta, 1990, 1032(2- 3), 157-176. (Pubitemid 120036336)
21. Brtko, J. [Mechanisms of the intracellular activities of thyroid gland hormones]. Vnitr. Lek., 2006, 52(10), 935-940. (Pubitemid 44545140)
22. Umesono, K.; Evans, R.M. Determinants of target gene specificity for steroid/thyroid hormone receptors. Cell, 1989, 57(7), 1139-1146. (Pubitemid 19169810)
23. De Luca, L.M. Retinoids and their receptors in differentiation, embryogenesis, and neoplasia. Faseb J., 1991, 5(14), 2924-2933. (Pubitemid 21905833)
24. Lotan, R. Retinoids and apoptosis: Implications for cancer chemoprevention and therapy. J. Natl. Cancer Inst., 1995, 87(22), 1655-1657.
25. Sun, S.Y.; Lotan, R. Retinoids as chemopreventive and therapeutic agents. Drugs of the Future, 1998, 23(6), 621.
26. Hinds, T.S.; West, W.L.; Knight, E.M. Carotenoids and retinoids: A review of research, clinical, and public health applications. J. Clin. Pharmacol., 1997, 37(7), 551-558. (Pubitemid 27443535)
27. Li, E.; Sucov, H.M.; Lee, K.F.; Evans, R.M.; Jaenisch, R. Normal development and growth of mice carrying a targeted disruption of the alpha 1 retinoic acid receptor gene. Proc. Natl. Acad. Sci. U S A, 1993, 90(4), 1590-1594. (Pubitemid 23058219)
28. Lufkin, T.; Lohnes, D.; Mark, M.; Dierich, A.; Gorry, P.; Gaub, M.P.; LeMeur, M.; Chambon, P. High postnatal lethality and testis degeneration in retinoic acid receptor alpha mutant mice. Proc. Natl. Acad. Sci. U S A, 1993, 90(15), 7225-7229. (Pubitemid 23222422)
29. Germain, P.; Chambon, P.; Eichele, G.; Evans, R.M.; Lazar, M.A.; Leid, M.; De Lera, A.R.; Lotan, R.; Mangelsdorf, D.J.; Gronemeyer, H. International Union of Pharmacology. LX. Retinoic acid receptors. Pharmacol. Rev., 2006, 58(4), 712-725. (Pubitemid 44833741)
30. Chapellier, B.; Mark, M.; Messaddeq, N.; Calleja, C.; Warot, X.; Brocard, J.; Gerard, C.; Li, M.; Metzger, D.; Ghyselinck, N.B.; Chambon, P. Physiological and retinoid-induced proliferations of epidermis basal keratinocytes are differently controlled. Embo. J., 2002, 21(13), 3402-3413. (Pubitemid 34760572)
31. Kastner, P.; Grondona, J.M.; Mark, M.; Gansmuller, A.; LeMeur, M.; Decimo, D.; Vonesch, J.L.; Dolle, P.; Chambon, P. Genetic analysis of RXR alpha developmental function: Convergence of RXR and RAR signaling pathways in heart and eye morphogenesis. Cell, 1994, 78(6), 987-1003.
32. Sucov, H.M.; Dyson, E.; Gumeringer, C.L.; Price, J.; Chien, K.R.; Evans, R.M. RXR alpha mutant mice establish a genetic basis for vitamin A signaling in heart morphogenesis. Genes Dev., 1994, 8(9), 1007-1018.
33. Germain, P.; Chambon, P.; Eichele, G.; Evans, R.M.; Lazar, M.A.; Leid, M.; De Lera, A.R.; Lotan, R.; Mangelsdorf, D.J.; Gronemeyer, H. International Union of Pharmacology. LXIII. Retinoid X receptors. Pharmacol. Rev., 2006, 58(4), 760-772. (Pubitemid 44833744)
34. Kastner, P.; Mark, M.; Leid, M.; Gansmuller, A.; Chin, W.; Grondona, J.M.; Decimo, D.; Krezel, W.; Dierich, A.; Chambon, P. Abnormal spermatogenesis in RXR beta mutant mice. Genes Dev., 1996, 10(1), 80-92.
35. Mascrez, B.; Ghyselinck, N.B.; Watanabe, M.; Annicotte, J.S.; Chambon, P.; Auwerx, J.; Mark, M. Ligand-dependent contribution of RXRbeta to cholesterol homeostasis in Sertoli cells. EMBO Rep., 2004, 5(3), 285-290. (Pubitemid 38500109)
36. Brown, N.S.; Smart, A.; Sharma, V.; Brinkmeier, M.L.; Greenlee, L.; Camper, S.A.; Jensen, D.R.; Eckel, R.H.; Krezel, W.; Chambon, P.; Haugen, B.R. Thyroid hormone resistance and increased metabolic rate in the RXR-gamma-deficient mouse. J. Clin. Invest., 2000, 106(1), 73-79. (Pubitemid 30437242)
37. Refetoff, S.; Weiss, R.E.; Usala, S.J. The syndromes of resistance to thyroid hormone. Endocr. Rev., 1993, 14(3), 348-399. (Pubitemid 23168055)
38. Klein, I.; Ojamaa, K. Thyrotoxicosis and the heart. Endocrinol. Metab. Clin. North Am., 1998, 27(1), 51-62. (Pubitemid 28144953)
39. Yen, P.M. Physiological and molecular basis of thyroid hormone action. Physiol. Rev., 2001, 81(3), 1097-1142. (Pubitemid 32606667)
40. Oppenheimer, J.H.; Schwartz, H.L.; Mariash, C.N.; Kinlaw, W.B.; Wong, N.C.; Freake, H.C. Advances in our understanding of thy roid hormone action at the cellular level. Endocr. Rev., 1987, 8(3), 288-308.
41. Ailhaud, G.; Grimaldi, P.; Negrel, R. Cellular and molecular aspects of adipose tissue development. Annu. Rev. Nutr., 1992, 12, 207-233.
42. Tuca, A.; Giralt, M.; Villarroya, F.; Vinas, O.; Mampel, T.; Iglesias, R. Ontogeny of thyroid hormone receptors and c-erbA expression during brown adipose tissue development: Evidence of fetal acquisition of the mature thyroid status. Endocrinology, 1993, 132(5), 1913-1920. (Pubitemid 23133235)
43. Yamada, M.; Rogers, D.; Wilber, J.F. Exogenous triiodothyronine lowers thyrotropin-releasing hormone concentrations in the specific hypothalamic nucleus (paraventricular) involved in thyrotropin regulation and also in posterior nucleus. Neuroendocrinology, 1989, 50(5), 560-563. (Pubitemid 19249100)
44. Chatterjee, V.K.; Lee, J.K.; Rentoumis, A.; Jameson, J.L. Negative regulation of the thyroid-stimulating hormone alpha gene by thyroid hormone: Receptor interaction adjacent to the TATA box. Proc. Natl. Acad. Sci. U S A, 1989, 86(23), 9114-9118. (Pubitemid 20010375)
45. Bernal, J. Iodine and brain development. Biofactors, 1999, 10(2-3), 271-276. (Pubitemid 29533840)
46. Oppenheimer, J.H.; Schwartz, H.L. Molecular basis of thyroid hormone-dependent brain development. Endocr. Rev., 1997, 18(4), 462-475. (Pubitemid 27349552)
47. Rivas, M.; Naranjo, J.R. Thyroid hormones, learning and memory. Genes Brain Behav., 2007, 6 Suppl 1, 40-44. (Pubitemid 46744110)
48. Davis, P.J.; Davis, F.B. Nongenomic actions of thyroid hormone. Thyroid, 1996, 6(5), 497-504. (Pubitemid 26398658)
49. Zhou, S.F. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin. Pharmacokinet., 2009, 48(11), 689-723.
50. Zhou, S.F. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part II. Clin. Pharmacokinet., 2009, 48(12), 761-804.
51. Klotz, U. Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: A review of a special problem. Int. J. Clin. Pharmacol. Ther., 2006, 44(7), 297-302. (Pubitemid 44043771)
52. Klotz, U. Impact of CYP2C19 polymorphisms on the clinical action of proton pump inhibitors (PPIs). Eur. J. Clin. Pharmacol., 2009, 65(1), 1-2.
53. Wojnowski, L.; Kamdem, L.K. Clinical implications of CYP3A polymorphisms. Expert Opin. Drug Metab. Toxicol., 2006, 2(2), 171-182. (Pubitemid 46372363)
54. Wang, J. CYP3A polymorphisms and immunosuppressive drugs in solid-organ transplantation. Expert Rev. Mol. Diagn., 2009, 9(4), 383-390.
55. Agundez, J.A. Cytochrome P450 gene polymorphism and cancer. Curr. Drug Metab., 2004, 5(3), 211-224. (Pubitemid 38735776)
56. Shi, X.; Zhou, S.; Wang, Z.; Zhou, Z.; Wang, Z. CYP1A1 and GSTM1 polymorphisms and lung cancer risk in Chinese populations: A meta-analysis. Lung Cancer, 2008, 59(2), 155-163. (Pubitemid 351173406)
57. Klotz, U. Pharmacokinetics and drug metabolism in the elderly. Drug Metab. Rev, 2009, 41(2), 67-76.
58. Scandlyn, M.J.; Stuart, E.C.; Rosengren, R.J. Sex-specific differences in CYP450 isoforms in humans. Expert Opin. Drug Metab. Toxicol., 2008, 4(4), 413-424. (Pubitemid 351728515)
59. Waxman, D.J.; O'Connor, C. Growth hormone regulation of sexdependent liver gene expression. Mol. Endocrinol., 2006, 20(11), 2613-2629. (Pubitemid 44833525)
60. Pavek, P.; Ceckova, M.; Staud, F. Variation of drug kinetics in pregnancy. Curr. Drug Metab., 2009, 10(5), 520-529.
61. Mitchell, S.C.; Smith, R.L.; Waring, R.H. The menstrual cycle and drug metabolism. Curr. Drug Metab., 2009, 10(5), 499-507.
62. Aitken, A.E.; Richardson, T.A.; Morgan, E.T. Regulation of drugmetabolizing enzymes and transporters in inflammation. Annu. Rev. Pharmacol. Toxicol., 2006, 46, 123-149. (Pubitemid 43271186)
63. Zordoky, B.N.; El-Kadi, A.O. Role of NF-kappaB in the regulation of cytochrome P450 enzymes. Curr. Drug Metab., 2009, 10(2), 164-178.
64. Renton, K.W. Regulation of drug metabolism and disposition during inflammation and infection. Expert Opin. Drug Metab. Toxicol., 2005, 1(4), 629-640.
65. Morgan, E.T. Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics. Clin. Pharmacol. Ther., 2009, 85(4), 434-438.
66. Croyle, M.A. Long-term virus-induced alterations of CYP3Amediated drug metabolism: A look at the virology, immunology and molecular biology of a multi-faceted problem. Expert Opin. Drug Metab. Toxicol., 2009, 5(10), 1189-1211.
67. Robertson, G.R.; Liddle, C.; Clarke, S.J. Inflammation and altered drug clearance in cancer: Transcriptional repression of a human CYP3A4 transgene in tumor-bearing mice. Clin. Pharmacol. Ther., 2008, 83(6), 894-897. (Pubitemid 351704929)
68. Kacevska, M.; Robertson, G.R.; Clarke, S.J.; Liddle, C. Inflammation and CYP3A4-mediated drug metabolism in advanced cancer: Impact and implications for chemotherapeutic drug dosing. Expert Opin. Drug Metab. Toxicol., 2008, 4(2), 137-149. (Pubitemid 351308413)
69. Assenat, E.; Gerbal-chaloin, S.; Maurel, P.; Vilarem, M.J.; Pascussi, J.M. Is nuclear factor kappa-B the missing link between inflammation, cancer and alteration in hepatic drug metabolism in patients with cancer? Eur. J. Cancer, 2006, 42(6), 785-792.
70. Pearson, E.R. Pharmacogenetics in diabetes. Curr. Diab. Rep., 2009, 9(2), 172-181.
71. Cheng, P.Y.; Morgan, E.T. Hepatic cytochrome P450 regulation in disease states. Curr. Drug Metab., 2001, 2(2), 165-183. (Pubitemid 32544553)
72. Nebert, D.W.; Dalton, T.P. The role of cytochrome P450 enzymes in endogenous signalling pathways and environmental carcinogenesis. Nat. Rev. Cancer, 2006, 6(12), 947-960. (Pubitemid 44862679)
73. Zhou, S.F. Potential strategies for minimizing mechanism-based inhibition of cytochrome P450 3A4. Curr. Pharm. Des., 2008, 14(10), 990-1000.
74. Zhou, S.F. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr. Drug Metab., 2008, 9(4), 310-322.
75. Masubuchi, Y.; Horie, T. Toxicological significance of mechanism- based inactivation of cytochrome p450 enzymes by drugs. Crit. Rev. Toxicol., 2007, 37(5), 389-412. (Pubitemid 47035212)
76. Lekas, P.; Tin, K.L.; Lee, C.; Prokipcak, R.D. The human cytochrome P450 1A1 mRNA is rapidly degraded in HepG2 cells. Arch. Biochem. Biophys., 2000, 384(2), 311-318. (Pubitemid 32012805)
77. Mattingly, C.J.; Toscano, W.A. Posttranscriptional silencing of cytochrome P4501A1 (CYP1A1) during zebrafish (Danio rerio) development. Dev. Dyn., 2001, 222(4), 645-654. (Pubitemid 33136335)
78. Elbekai, R.H.; El-Kadi, A.O. Transcriptional activation and posttranscriptional modification of Cyp1a1 by arsenite, cadmium, and chromium. Toxicol. Lett., 2007, 172(3), 106-119. (Pubitemid 47187594)
79. Raffalli-Mathieu, F.; Geneste, O.; Lang, M.A. Characterization of two nuclear proteins that interact with cytochrome P-450 1A2 mRNA. Regulation of RNA binding and possible role in the expression of the Cyp1a2 gene. Eur. J. Biochem., 1997, 245(1), 17-24. (Pubitemid 27142258)
80. Delaporte, E.; Renton, K.W. Cytochrome P4501A1 and cytochrome P4501A2 are downregulated at both transcriptional and post-transcriptional levels by conditions resulting in interferonalpha/ beta induction. Life Sci., 1997, 60(10), 787-796. (Pubitemid 27087271)
81. Daujat, M.; Clair, P.; Astier, C.; Fabre, I.; Pineau, T.; Yerle, M.; Gellin, J.; Maurel, P. Induction, regulation and messenger half-life of cytochromes P450 IA1, IA2 and IIIA6 in primary cultures of rabbit hepatocytes. CYP 1A1, 1A2 and 3A6 chromosome location in the rabbit and evidence that post-transcriptional control of gene IA2 does not involve mRNA stabilization. Eur. J. Biochem., 1991, 200(2), 501-510.
82. Pan, J.; Hong, J.Y.; Yang, C.S. Post-transcriptional regulation of mouse renal cytochrome P450 2E1 by testosterone. Arch. Biochem. Biophys., 1992, 299(1), 110-115.
83. Freeman, J.E.; Wolf, C.R. Evidence against a role for serine 129 in determining murine cytochrome P450 Cyp2e-1 protein levels. Biochemistry, 1994, 33(47), 13963-13966. (Pubitemid 24382336)
84. Martini, R.; Ingelman-Sundberg, M.; Murray, M. Pretranslational and posttranslational regulation of rat hepatic CYPs 3A2 and 2E1 by disulfiram. Biochem. Pharmacol., 1997, 54(12), 1323-1329. (Pubitemid 27521043)
85. Bandiera, S.; Weidlich, S.; Harth, V.; Broede, P.; Ko, Y.; Friedberg, T. Proteasomal degradation of human CYP1B1: Effect of the Asn453Ser polymorphism on the post-translational regulation of CYP1B1 expression. Mol. Pharmacol., 2005, 67(2), 435-443. (Pubitemid 40216736)
86. Lee, C.M.; Kim, B.Y.; Li, L.; Morgan, E.T. Nitric oxide-dependent proteasomal degradation of cytochrome P450 2B proteins. J. Biol. Chem., 2008, 283(2), 889-898.
87. Morishima, Y.; Peng, H.M.; Lin, H.L.; Hollenberg, P.F.; Sunahara, R.K.; Osawa, Y.; Pratt, W.B. Regulation of cytochrome P450 2E1 by heat shock protein 90-dependent stabilization and CHIP dependent proteasomal degradation. Biochemistry, 2005, 44(49), 16333-16340. (Pubitemid 41785832)
88. Huan, J.Y.; Streicher, J.M.; Bleyle, L.A.; Koop, D.R. Proteasomedependent degradation of cytochromes P450 2E1 and 2B1 expressed in tetracycline-regulated HeLa cells. Toxicol. Appl. Pharmacol., 2004, 199(3), 332-343. (Pubitemid 39208732)
89. Zangar, R.C.; Kimzey, A.L.; Okita, J.R.; Wunschel, D.S.; Edwards, R.J.; Kim, H.; Okita, R.T. Cytochrome P450 3A conjugation to ubiquitin in a process distinct from classical ubiquitination pathway. Mol. Pharmacol., 2002, 61(4), 892-904. (Pubitemid 34273170)
90. Zangar, R.C.; Bollinger, N.; Verma, S.; Karin, N.J.; Lu, Y. The nuclear factor-kappa B pathway regulates cytochrome P450 3A4 protein stability. Mol. Pharmacol., 2008, 73(6), 1652-1658. (Pubitemid 351724354)
91. Guenthner, T.M.; Nebert, D.W. Cytosolic receptor for aryl hydrocarbon hydroxylase induction by polycyclic aromatic compounds. Evidence for structural and regulatory variants among established cell cultured lines. J. Biol. Chem., 1977, 252(24), 8981-8989. (Pubitemid 8254843)
92. Pavek, P.; Dvorak, Z. Xenobiotic-induced transcriptional regulation of xenobiotic metabolizing enzymes of the cytochrome P450 superfamily in human extrahepatic tissues. Curr. Drug Metab., 2008, 9(2), 129-143. (Pubitemid 351461002)
93. Denison, M.S.; Nagy, S.R. Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemicals. Annu. Rev. Pharmacol. Toxicol., 2003, 43, 309-334. (Pubitemid 37372644)
94. Bachleda, P.; Dvorak, Z. Pharmacological inhibitors of JNK and ERK kinases SP600125 and U0126 are not appropriate tools for studies of drug metabolism because they activate aryl hydrocarbon receptor. Gen. Physiol. Biophys., 2008, 27(2), 143-145.
95. Dvorak, Z.; Vrzal, R.; Henklova, P.; Jancova, P.; Anzenbacherova, E.; Maurel, P.; Svecova, L.; Pavek, P.; Ehrmann, J.; Havlik, R.; Bednar, P.; Lemr, K.; Ulrichova, J. JNK inhibitor SP600125 is a partial agonist of human aryl hydrocarbon receptor and induces CYP1A1 and CYP1A2 genes in primary human hepatocytes. Biochem. Pharmacol., 2008, 75(2), 580-588. (Pubitemid 350298475)
96. Joiakim, A.; Mathieu, P.A.; Palermo, C.; Gasiewicz, T.A.; Reiners, J.J., Jr. The Jun N-terminal kinase inhibitor SP600125 is a ligand and antagonist of the aryl hydrocarbon receptor. Drug Metab. Dispos., 2003, 31(11), 1279-1282. (Pubitemid 37310311)
97. Andrieux, L.; Langouet, S.; Fautrel, A.; Ezan, F.; Krauser, J.A.; Savouret, J.F.; Guengerich, F.P.; Baffet, G.; Guillouzo, A. Aryl hydrocarbon receptor activation and cytochrome P450 1A induction by the mitogen-activated protein kinase inhibitor U0126 in hepatocytes. Mol. Pharmacol., 2004, 65(4), 934-943. (Pubitemid 38420499)
98. Daujat, M.; Peryt, B.; Lesca, P.; Fourtanier, G.; Domergue, J.; Maurel, P. Omeprazole, an inducer of human CYP1A1 and 1A2, is not a ligand for the Ah receptor. Biochem. Biophys. Res. Commun., 1992, 188(2), 820-825.
99. Murray, I.A.; Perdew, G.H. Omeprazole stimulates the induction of human insulin-like growth factor binding protein-1 through aryl hydrocarbon receptor activation. J. Pharmacol. Exp. Ther., 2008, 324(3), 1102-1110. (Pubitemid 351397862)
100. Yoshinari, K.; Ueda, R.; Kusano, K.; Yoshimura, T.; Nagata, K.; Yamazoe, Y. Omeprazole transactivates human CYP1A1 and CYP1A2 expression through the common regulatory region containing multiple xenobiotic-responsive elements. Biochem. Pharmacol., 2008, 76(1), 139-145.
101. Curi-Pedrosa, R.; Daujat, M.; Pichard, L.; Ourlin, J.C.; Clair, P.; Gervot, L.; Lesca, P.; Domergue, J.; Joyeux, H.; Fourtanier, G.; et al. Omeprazole and lansoprazole are mixed inducers of CYP1A and CYP3A in human hepatocytes in primary culture. J. Pharmacol. Exp. Ther., 1994, 269(1), 384-392. (Pubitemid 24143278)
102. Daujat, M.; Charrasse, S.; Fabre, I.; Lesca, P.; Jounaidi, Y.; Larroque, C.; Poellinger, L.; Maurel, P. Induction of CYP1A1 gene by benzimidazole derivatives during Caco-2 cell differentiation. Evidence for an aryl-hydrocarbon receptor-mediated mechanism. Eur. J. Biochem., 1996, 237(3), 642-652.
103. Matsuoka-Kawano, K.; Yoshinari, K.; Nagayama, S.; Yamazoe, Y. TSU-16, (Z)-3- [(2,4-dimethylpyrrol-5-yl)methylidenyl]-2- indolinone, is a potent activator of aryl hydrocarbon receptor and increases CYP1A1 and CYP1A2 expression in human hepatocytes. Chem. Biol. Interact., 2010, 185(1), 33-41.
104. Revel, A.; Raanani, H.; Younglai, E.; Xu, J.; Rogers, I.; Han, R.; Savouret, J.F.; Casper, R.F. Resveratrol, a natural aryl hydrocarbon receptor antagonist, protects lung from DNA damage and apoptosis caused by benzo [a]pyrene. J. Appl. Toxicol., 2003, 23(4), 255-261. (Pubitemid 36950295)
105. Vrzal, R.; Zdarilova, A.; Ulrichova, J.; Blaha, L.; Giesy, J.P.; Dvorak, Z. Activation of the aryl hydrocarbon receptor by berberine in HepG2 and H4IIE cells: Biphasic effect on CYP1A1. Biochem. Pharmacol., 2005, 70(6), 925-936. (Pubitemid 41138858)
106. Fukuda, I.; Mukai, R.; Kawase, M.; Yoshida, K.; Ashida, H. Interaction between the aryl hydrocarbon receptor and its antagonists, flavonoids. Biochem. Biophys. Res. Commun., 2007, 359(3), 822-827. (Pubitemid 46899026)
107. Amakura, Y.; Tsutsumi, T.; Sasaki, K.; Nakamura, M.; Yoshida, T.; Maitani, T. Influence of food polyphenols on aryl hydrocarbon receptor- signaling pathway estimated by in vitro bioassay. Phytochemistry, 2008, 69(18), 3117-3130.
108. Ashida, H.; Nishiumi, S.; Fukuda, I. An update on the dietary ligands of the AhR. Expert Opin. Drug Metab. Toxicol., 2008, 4(11), 1429-1447.
109. Moon, Y.J.; Wang, X.; Morris, M.E. Dietary flavonoids: Effects on xenobiotic and carcinogen metabolism. Toxicol. In Vitro, 2006, 20(2), 187-210. (Pubitemid 43087702)
110. Nguyen, L.P.; Bradfield, C.A. The search for endogenous activators of the aryl hydrocarbon receptor. Chem. Res. Toxicol., 2008, 21(1), 102-116. (Pubitemid 351219712)
111. Sinal, C.J.; Bend, J.R. Aryl hydrocarbon receptor-dependent induction of cyp1a1 by bilirubin in mouse hepatoma hepa 1c1c7 cells. Mol. Pharmacol., 1997, 52(4), 590-599. (Pubitemid 27443980)
112. Phelan, D.; Winter, G.M.; Rogers, W.J.; Lam, J.C.; Denison, M.S. Activation of the Ah receptor signal transduction pathway by bilirubin and biliverdin. Arch. Biochem. Biophys., 1998, 357(1), 155-163. (Pubitemid 28402597)
113. Adachi, J.; Mori, Y.; Matsui, S.; Takigami, H.; Fujino, J.; Kitagawa, H.; Miller, C.A., 3rd; Kato, T.; Saeki, K.; Matsuda, T. Indirubin and indigo are potent aryl hydrocarbon receptor ligands present in human urine. J. Biol. Chem., 2001, 276(34), 31475-31478.
114. Wincent, E.; Amini, N.; Luecke, S.; Glatt, H.; Bergman, J.; Crescenzi, C.; Rannug, A.; Rannug, U. The suggested physiologic aryl hydrocarbon receptor activator and cytochrome P4501 substrate 6- formylindolo [3,2-b]carbazole is present in humans. J. Biol. Chem., 2009, 284(5), 2690-2696.
115. Wincent, E.; Shirani, H.; Bergman, J.; Rannug, U.; Janosik, T. Synthesis and biological evaluation of fused thio- and selenopyrans as new indolocarbazole analogues with aryl hydrocarbon receptor affinity. Bioorg. Med. Chem., 2009, 17(4), 1648-1653.
116. Rifkind, A.B. CYP1A in TCDD toxicity and in physiology-with particular reference to CYP dependent arachidonic acid metabolism and other endogenous substrates. Drug Metab. Rev., 2006, 38(1-2), 291-335. (Pubitemid 43739012)
117. Chiaro, C.R.; Morales, J.L.; Prabhu, K.S.; Perdew, G.H. Leukotriene A4 metabolites are endogenous ligands for the Ah receptor. Biochemistry, 2008, 47(32), 8445-8455.
118. Chiaro, C.R.; Patel, R.D.; Perdew, G.H. 12(R)-Hydroxy- 5(Z),8(Z),10(E),14(Z)-eicosatetraenoic acid [12(R)-HETE], an arachidonic acid derivative, is an activator of the aryl hydrocarbon receptor. Mol. Pharmacol., 2008, 74(6), 1649-1656.
119. Seidel, S.D.; Winters, G.M.; Rogers, W.J.; Ziccardi, M.H.; Li, V.; Keser, B.; Denison, M.S. Activation of the Ah receptor signaling pathway by prostaglandins. J. Biochem. Mol. Toxicol., 2001, 15(4), 187-196. (Pubitemid 32734325)
120. Harper, P.A.; Riddick, D.S.; Okey, A.B. Regulating the regulator: Factors that control levels and activity of the aryl hydrocarbon receptor. Biochem .Pharmacol., 2006, 72(3), 267-279. (Pubitemid 43975077)
121. Puga, A.; Ma, C.; Marlowe, J.L. The aryl hydrocarbon receptor cross-talks with multiple signal transduction pathways. Biochem Pharmacol, 2009, 77(4), 713-722.
122. Marlowe, J.L.; Puga, A. Aryl hydrocarbon receptor, cell cycle regulation, toxicity, and tumorigenesis. J. Cell Biochem., 2005, 96(6), 1174-1184. (Pubitemid 41681860)
123. Bock, K.W.; Kohle, C. Ah receptor- and TCDD-mediated liver tumor promotion: Clonal selection and expansion of cells evading growth arrest and apoptosis. Biochem. Pharmacol., 2005, 69(10), 1403-1408. (Pubitemid 40602440)
124. Esser, C. The immune phenotype of AhR null mouse mutants: Not a simple mirror of xenobiotic receptor over-activation. Biochem. Pharmacol., 2009, 77(4), 597-607.
125. Esser, C.; Rannug, A.; Stockinger, B. The aryl hydrocarbon receptor in immunity. Trends Immunol., 2009, 30(9), 447-454.
126. Head, J.L.; Lawrence, B.P. The aryl hydrocarbon receptor is a modulator of anti-viral immunity. Biochem. Pharmacol., 2009, 77(4), 642-653.
127. Shimba, S.; Watabe, Y. Crosstalk between the AHR signaling pathway and circadian rhythm. Biochem. Pharmacol., 2009, 77(4), 560-565.
128. Gasiewicz, T.A.; Henry, E.C.; Collins, L.L. Expression and activity of aryl hydrocarbon receptors in development and cancer. Crit. Rev. Eukaryot. Gene Expr., 2008, 18(4), 279-321. (Pubitemid 351991362)
129. Ray, S.; Swanson, H.I. Activation of the aryl hydrocarbon receptor by TCDD inhibits senescence: A tumor promoting event? Biochem. Pharmacol., 2009, 77(4), 681-688.
130. Gouedard, C.; Barouki, R.; Morel, Y. Induction of the paraoxonase- 1 gene expression by resveratrol. Arterioscler. Thromb. Vasc. Biol., 2004, 24(12), 2378-2383. (Pubitemid 39658045)
131. Gouedard, C.; Barouki, R.; Morel, Y. Dietary polyphenols increase paraoxonase 1 gene expression by an aryl hydrocarbon receptordependent mechanism. Mol. Cell Biol., 2004, 24(12), 5209-5222. (Pubitemid 38738157)
132. Ohtake, F.; Fujii-Kuriyama, Y.; Kato, S. AhR acts as an E3 ubiquitin ligase to modulate steroid receptor functions. Biochem. Pharmacol., 2009, 77(4), 474-484.
133. Ohtake, F.; Baba, A.; Takada, I.; Okada, M.; Iwasaki, K.; Miki, H.; Takahashi, S.; Kouzmenko, A.; Nohara, K.; Chiba, T.; Fujii- Kuriyama, Y.; Kato, S. Dioxin receptor is a ligand-dependent E3 ubiquitin ligase. Nature, 2007, 446(7135), 562-566. (Pubitemid 46514731)
134. Henklova, P.; Vrzal, R.; Ulrichova, J.; Dvorak, Z. Role of mitogenactivated protein kinases in aryl hydrocarbon receptor signaling. Chem. Biol. Interact., 2008, 172(2), 93-104.
135. McGuire, J.; Whitelaw, M.L.; Pongratz, I.; Gustafsson, J.A.; Poellinger, L. A cellular factor stimulates ligand-dependent release of hsp90 from the basic helix-loop-helix dioxin receptor. Mol. Cell Biol., 1994, 14(4), 2438-2446. (Pubitemid 24108226)
136. Lees, M.J.; Whitelaw, M.L. Multiple roles of ligand in transforming the dioxin receptor to an active basic helix-loop-helix/PAS transcription factor complex with the nuclear protein Arnt. Mol. Cell Biol., 1999, 19(8), 5811-5822. (Pubitemid 29339935)
137. Heid, S.E.; Pollenz, R.S.; Swanson, H.I. Role of heat shock protein 90 dissociation in mediating agonist-induced activation of the aryl hydrocarbon receptor. Mol. Pharmacol., 2000, 57(1), 82-92. (Pubitemid 30033263)
138. Pollenz, R.S.; Sattler, C.A.; Poland, A. The aryl hydrocarbon receptor and aryl hydrocarbon receptor nuclear translocator protein show distinct subcellular localizations in Hepa 1c1c7 cells by immunofluorescence microscopy. Mol. Pharmacol., 1994, 45(3), 428-438. (Pubitemid 24094931)
139. Kliewer, S.A.; Moore, J.T.; Wade, L.; Staudinger, J.L.; Watson, M.A.; Jones, S.A.; McKee, D.D.; Oliver, B.B.; Willson, T.M.; Zetterstrom, R.H.; Perlmann, T.; Lehmann, J.M. An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell, 1998, 92(1), 73-82. (Pubitemid 28053299)
140. Lehmann, J.M.; McKee, D.D.; Watson, M.A.; Willson, T.M.; Moore, J.T.; Kliewer, S.A. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J. Clin. Invest., 1998, 102(5), 1016-1023. (Pubitemid 28419246)
141. Bertilsson, G.; Heidrich, J.; Svensson, K.; Asman, M.; Jendeberg, L.; Sydow-Backman, M.; Ohlsson, R.; Postlind, H.; Blomquist, P.; Berkenstam, A. Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction. Proc. Natl. Acad. Sci. U S A, 1998, 95(21), 12208-12213. (Pubitemid 28483744)
142. Schuetz, E.G.; Brimer, C.; Schuetz, J.D. Environmental xenobiotics and the antihormones cyproterone acetate and spironolactone use the nuclear hormone pregnenolone X receptor to activate the CYP3A23 hormone response element. Mol. Pharmacol., 1998, 54(6), 1113-1117. (Pubitemid 29002056)
143. Pascussi, J.M.; Jounaidi, Y.; Drocourt, L.; Domergue, J.; Balabaud, C.; Maurel, P.; Vilarem, M.J. Evidence for the presence of a functional pregnane X receptor response element in the CYP3A7 promoter gene. Biochem. Biophys. Res. Commun., 1999, 260(2), 377-381. (Pubitemid 29352073)
144. Jones, S.A.; Moore, L.B.; Shenk, J.L.; Wisely, G.B.; Hamilton, G.A.; McKee, D.D.; Tomkinson, N.C.; LeCluyse, E.L.; Lambert, M.H.; Willson, T.M.; Kliewer, S.A.; Moore, J.T. The pregnane X receptor: A promiscuous xenobiotic receptor that has diverged during evolution. Mol. Endocrinol., 2000, 14(1), 27-39. (Pubitemid 32260325)
145. Watkins, R.E.; Wisely, G.B.; Moore, L.B.; Collins, J.L.; Lambert, M.H.; Williams, S.P.; Willson, T.M.; Kliewer, S.A.; Redinbo, M.R. The human nuclear xenobiotic receptor PXR: Structural determinants of directed promiscuity. Science, 2001, 292(5525), 2329-2333. (Pubitemid 32568055)
146. Watkins, R.E.; Maglich, J.M.; Moore, L.B.; Wisely, G.B.; Noble, S.M.; Davis-Searles, P.R.; Lambert, M.H.; Kliewer, S.A.; Redinbo, M.R. 2.1 A crystal structure of human PXR in complex with the St. John's wort compound hyperforin. Biochemistry, 2003, 42(6), 1430-1438. (Pubitemid 36205949)
147. Pascussi, J.M.; Gerbal-Chaloin, S.; Drocourt, L.; Maurel, P.; Vilarem, M.J. The expression of CYP2B6, CYP2C9 and CYP3A4 genes: A tangle of networks of nuclear and steroid receptors. Biochim. Biophys. Acta, 2003, 1619(3), 243-253. (Pubitemid 36163419)
148. Pascussi, J.M.; Gerbal-Chaloin, S.; Duret, C.; Daujat-Chavanieu, M.; Vilarem, M.J.; Maurel, P. The tangle of nuclear receptors that controls xenobiotic metabolism and transport: Crosstalk and consequences. Annu. Rev. Pharmacol. Toxicol., 2008, 48, 1-32. (Pubitemid 351738147)
149. Wan, Y.J.; An, D.; Cai, Y.; Repa, J.J.; Hung-Po Chen, T.; Flores, M.; Postic, C.; Magnuson, M.A.; Chen, J.; Chien, K.R.; French, S.; Mangelsdorf, D.J.; Sucov, H.M. Hepatocyte-specific mutation establishes retinoid X receptor alpha as a heterodimeric integrator of multiple physiological processes in the liver. Mol. Cell Biol., 2000, 20(12), 4436-4444. (Pubitemid 30346638)
150. Svecova, L.; Vrzal, R.; Burysek, L.; Anzenbacherova, E.; Cerveny, L.; Grim, J.; Trejtnar, F.; Kunes, J.; Pour, M.; Staud, F.; Anzenbacher, P.; Dvorak, Z.; Pavek, P. Azole antimycotics differentially affect rifampicin-induced pregnane X receptor-mediated CYP3A4 gene expression. Drug Metab. Dispos., 2008, 36(2), 339-348. (Pubitemid 351185746)
151. Luo, G.; Cunningham, M.; Kim, S.; Burn, T.; Lin, J.; Sinz, M.; Hamilton, G.; Rizzo, C.; Jolley, S.; Gilbert, D.; Downey, A.; Mudra, D.; Graham, R.; Carroll, K.; Xie, J.; Madan, A.; Parkinson, A.; Christ, D.; Selling, B.; LeCluyse, E.; Gan, L.S. CYP3A4 induction by drugs: Correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab. Dispos., 2002, 30(7), 795-804. (Pubitemid 34671092)
152. Cerveny, L.; Svecova, L.; Anzenbacherova, E.; Vrzal, R.; Staud, F.; Dvorak, Z.; Ulrichova, J.; Anzenbacher, P.; Pavek, P. Valproic acid induces CYP3A4 and MDR1 gene expression by activation of constitutive androstane receptor and pregnane X receptor pathways. Drug Metab. Dispos., 2007, 35(7), 1032-1041. (Pubitemid 46956421)
153. Vrzal, R.; Kubesova, K.; Pavek, P.; Dvorak, Z. Benzodiazepines medazepam and midazolam are activators of pregnane X receptor and weak inducers of CYP3A4: Investigation in primary cultures of human hepatocytes and hepatocarcinoma cell lines. Toxicol. Lett., 2010, 193(2), 183-188.
154. Drocourt, L.; Pascussi, J.M.; Assenat, E.; Fabre, J.M.; Maurel, P.; Vilarem, M.J. Calcium channel modulators of the dihydropyridine family are human pregnane X receptor activators and inducers of CYP3A, CYP2B, and CYP2C in human hepatocytes. Drug Metab. Dispos., 2001, 29(10), 1325-1331. (Pubitemid 32896582)
155. Waxman, D.J. P450 gene induction by structurally diverse xenochemicals: Central role of nuclear receptors CAR, PXR, and PPAR. Arch. Biochem. Biophys., 1999, 369(1), 11-23. (Pubitemid 29434534)
156. Ngan, C.H.; Beglov, D.; Rudnitskaya, A.N.; Kozakov, D.; Waxman, D.J.; Vajda, S. The structural basis of pregnane X receptor binding promiscuity. Biochemistry, 2009, 48(48), 11572-11581.
157. Chang, T.K. Activation of pregnane X receptor (PXR) and constitutive androstane receptor (CAR) by herbal medicines. Aaps J., 2009, 11(3), 590-601.
158. Mnif, W.; Pascussi, J.M.; Pillon, A.; Escande, A.; Bartegi, A.; Nicolas, J.C.; Cavailles, V.; Duchesne, M.J.; Balaguer, P. Estrogens and antiestrogens activate hPXR. Toxicol. Lett., 2007, 170(1), 19-29. (Pubitemid 46509749)
159. Hurst, C.H.; Waxman, D.J. Environmental phthalate monoesters activate pregnane X receptor-mediated transcription. Toxicol. Appl. Pharmacol., 2004, 199(3), 266-274. (Pubitemid 39208726)
160. Wyde, M.E.; Kirwan, S.E.; Zhang, F.; Laughter, A.; Hoffman, H.B.; Bartolucci-Page, E.; Gaido, K.W.; Yan, B.; You, L. Di-nbutyl phthalate activates constitutive androstane receptor and pregnane X receptor and enhances the expression of steroidmetabolizing enzymes in the liver of rat fetuses. Toxicol. Sci., 2005, 86(2), 281-290. (Pubitemid 41418641)
161. Traber, M.G. Vitamin E, nuclear receptors and xenobiotic metabolism. Arch. Biochem. Biophys., 2004, 423(1), 6-11. (Pubitemid 38198208)
162. Landes, N.; Pfluger, P.; Kluth, D.; Birringer, M.; Ruhl, R.; Bol, G.F.; Glatt, H.; Brigelius-Flohe, R. Vitamin E activates gene ex pression via the pregnane X receptor. Biochem. Pharmacol., 2003, 65(2), 269-273. (Pubitemid 36015829)
163. Igarashi, M.; Yogiashi, Y.; Mihara, M.; Takada, I.; Kitagawa, H.; Kato, S. Vitamin K induces osteoblast differentiation through pregnane X receptor-mediated transcriptional control of the Msx2 gene. Mol. Cell Biol., 2007, 27(22), 7947-7954. (Pubitemid 350086427)
164. Ruhl, R. Induction of PXR-mediated metabolism by beta-carotene. Biochim. Biophys. Acta, 2005, 1740(2), 162-169.
165. Zollner, G.; Marschall, H.U.; Wagner, M.; Trauner, M. Role of nuclear receptors in the adaptive response to bile acids and cholestasis: Pathogenetic and therapeutic considerations. Mol. Pharm., 2006, 3(3), 231-251. (Pubitemid 44021431)
166. Barbier, O.; Trottier, J.; Kaeding, J.; Caron, P.; Verreault, M. Lipid-activated transcription factors control bile acid glucuronidation. Mol. Cell Biochem., 2009, 326(1-2), 3-8.
167. Rushmore, T.H.; Kong, A.N. Pharmacogenomics, regulation and signaling pathways of phase I and II drug metabolizing enzymes. Curr. Drug Metab., 2002, 3(5), 481-490. (Pubitemid 34987481)
168. Zhou, J.; Zhang, J.; Xie, W. Xenobiotic nuclear receptor-mediated regulation of UDP-glucuronosyl-transferases. Curr. Drug Metab., 2005, 6(4), 289-298. (Pubitemid 41086763)
169. Dixit, S.G.; Tirona, R.G.; Kim, R.B. Beyond CAR and PXR. Curr. Drug Metab., 2005, 6(4), 385-397. (Pubitemid 41086770)
170. Runge-Morris, M.; Kocarek, T.A. Regulation of sulfotransferases by xenobiotic receptors. Curr. Drug Metab., 2005, 6(4), 299-307. (Pubitemid 41086764)
171. Klaassen, C.D.; Slitt, A.L. Regulation of hepatic transporters by xenobiotic receptors. Curr. Drug Metab., 2005, 6(4), 309-328. (Pubitemid 41086765)
172. Xu, C.; Li, C.Y.; Kong, A.N. Induction of phase I, II and III drug metabolism/transport by xenobiotics. Arch. Pharm. Res., 2005, 28(3), 249-268. (Pubitemid 44698742)
173. Bock, K.W.; Bock-Hennig, B.S. UDP-glucuronosyltransferases (UGTs): From purification of Ah-receptor-inducible UGT1A6 to coordinate regulation of subsets of CYPs, UGTs, and ABC transporters by nuclear receptors. Drug Metab. Rev., 2009.
174. Kohle, C.; Bock, K.W. Coordinate regulation of human drugmetabolizing enzymes, and conjugate transporters by the Ah receptor, pregnane X receptor and constitutive androstane receptor. Biochem. Pharmacol., 2009, 77(4), 689-699.
175. Urquhart, B.L.; Tirona, R.G.; Kim, R.B. Nuclear receptors and the regulation of drug-metabolizing enzymes and drug transporters: Implications for interindividual variability in response to drugs. J. Clin. Pharmacol., 2007, 47(5), 566-578. (Pubitemid 46632158)
176. Konno, Y.; Negishi, M.; Kodama, S. The roles of nuclear receptors CAR and PXR in hepatic energy metabolism. Drug Metab. Pharmacokinet., 2008, 23(1), 8-13.
177. di Masi, A.; Marinis, E.D.; Ascenzi, P.; Marino, M. Nuclear receptors CAR and PXR: Molecular, functional, and biomedical aspects. Mol. Aspects Med., 2009, 30(5), 297-343.
178. Moreau, A.; Vilarem, M.J.; Maurel, P.; Pascussi, J.M. Xenoreceptors CAR and PXR activation and consequences on lipid metabolism, glucose homeostasis, and inflammatory response. Mol. Pharm., 2008, 5(1), 35-41. (Pubitemid 351300032)
179. Wada, T.; Gao, J.; Xie, W. PXR and CAR in energy metabolism. Trends Endocrinol. Metab., 2009, 20(6), 273-279.
180. Kakizaki, S.; Yamazaki, Y.; Takizawa, D.; Negishi, M. New insights on the xenobiotic-sensing nuclear receptors in liver diseases- CAR and PXR. Curr. Drug Metab., 2008, 9(7), 614-621.
181. Roth, A.; Looser, R.; Kaufmann, M.; Blattler, S.M.; Rencurel, F.; Huang, W.; Moore, D.D.; Meyer, U.A. Regulatory cross-talk between drug metabolism and lipid homeostasis: Constitutive androstane receptor and pregnane X receptor increase Insig-1 expression. Mol. Pharmacol., 2008, 73(4), 1282-1289. (Pubitemid 351439210)
182. Moreau, A.; Teruel, C.; Beylot, M.; Albalea, V.; Tamasi, V.; Umbdenstock, T.; Parmentier, Y.; Sa-Cunha, A.; Suc, B.; Fabre, J.M.; Navarro, F.; Ramos, J.; Meyer, U.; Maurel, P.; Vilarem, M.J.; Pascussi, J.M. A novel pregnane X receptor and S14-mediated lipogenic pathway in human hepatocyte. Hepatology, 2009, 49(6), 2068-2079.
183. Honkakoski, P.; Zelko, I.; Sueyoshi, T.; Negishi, M. The nuclear orphan receptor CAR-retinoid X receptor heterodimer activates the phenobarbital- responsive enhancer module of the CYP2B gene. Mol. Cell Biol., 1998, 18(10), 5652-5658. (Pubitemid 28450516)
184. Sueyoshi, T.; Kawamoto, T.; Zelko, I.; Honkakoski, P.; Negishi, M. The repressed nuclear receptor CAR responds to phenobarbital in activating the human CYP2B6 gene. J. Biol. Chem., 1999, 274(10), 6043-6046. (Pubitemid 29111006)
185. Kawamoto, T.; Sueyoshi, T.; Zelko, I.; Moore, R.; Washburn, K.; Negishi, M. Phenobarbital-responsive nuclear translocation of the receptor CAR in induction of the CYP2B gene. Mol. Cell Biol., 1999, 19(9), 6318-6322. (Pubitemid 29399336)
186. Yoshinari, K.; Kobayashi, K.; Moore, R.; Kawamoto, T.; Negishi, M. Identification of the nuclear receptor CAR:HSP90 complex in mouse liver and recruitment of protein phosphatase 2A in response to phenobarbital. FEBS Lett., 2003, 548(1-3), 17-20. (Pubitemid 37281243)
187. Sueyoshi, T.; Moore, R.; Sugatani, J.; Matsumura, Y.; Negishi, M. PPP1R16A, the membrane subunit of protein phosphatase 1beta, signals nuclear translocation of the nuclear receptor constitutive active/ androstane receptor. Mol. Pharmacol., 2008, 73(4), 1113-1121. (Pubitemid 351439193)
188. Sueyoshi, T.; Negishi, M. Phenobarbital response elements of cytochrome P450 genes and nuclear receptors. Annu. Rev. Pharmacol. Toxicol., 2001, 41, 123-143. (Pubitemid 32385885)
189. Auerbach, S.S.; Stoner, M.A.; Su, S.; Omiecinski, C.J. Retinoid X receptor-alpha-dependent transactivation by a naturally occurring structural variant of human constitutive androstane receptor (NR1I3). Mol. Pharmacol., 2005, 68(5), 1239-1253. (Pubitemid 41539981)
190. Chang, T.K.; Waxman, D.J. Synthetic drugs and natural products as modulators of constitutive androstane receptor (CAR) and pregnane X receptor (PXR). Drug Metab. Rev., 2006, 38(1-2), 51-73. (Pubitemid 43738999)
191. Willson, T.M.; Kliewer, S.A. PXR, CAR and drug metabolism. Nat. Rev. Drug Discov., 2002, 1(4), 259-266.
192. Safe, S.; Wormke, M. Inhibitory aryl hydrocarbon receptorestrogen receptor alpha cross-talk and mechanisms of action. Chem. Res. Toxicol., 2003, 16(7), 807-816. (Pubitemid 36898994)
193. Dvorak, Z.; Pavek, P. Regulation of drug-metabolizing cytochrome P450 enzymes by glucocorticoids. Drug Metab. Rev., 2010, 42(4), 621-635.
194. Beischlag, T.V.; Taylor, R.T.; Rose, D.W.; Yoon, D.; Chen, Y.; Lee, W.H.; Rosenfeld, M.G.; Hankinson, O. Recruitment of thyroid hormone receptor/retinoblastoma-interacting protein 230 by the aryl hydrocarbon receptor nuclear translocator is required for the transcriptional response to both dioxin and hypoxia. J. Biol. Chem., 2004, 279(52), 54620-54628. (Pubitemid 40053205)
195. Monostory, K.; Pascussi, J.M.; Kobori, L.; Dvorak, Z. Hormonal regulation of CYP1A expression. Drug Metab. Rev., 2009, 41(4), 547-572.
196. Murphy, K.A.; Quadro, L.; White, L.A. The intersection between the aryl hydrocarbon receptor (AhR)- and retinoic acid-signaling pathways. Vitam. Horm., 2007, 75, 33-67.
197. Fallone, F.; Villard, P.H.; Seree, E.; Rimet, O.; Nguyen, Q.B.; Bourgarel-Rey, V.; Fouchier, F.; Barra, Y.; Durand, A.; Lacarelle, B. Retinoids repress Ah receptor CYP1A1 induction pathway through the SMRT corepressor. Biochem. Biophys. Res. Commun., 2004, 322(2), 551-556. (Pubitemid 39490339)
198. Seree, E.; Villard, P.H.; Pascussi, J.M.; Pineau, T.; Maurel, P.; Nguyen, Q.B.; Fallone, F.; Martin, P.M.; Champion, S.; Lacarelle, B.; Savouret, J.F.; Barra, Y. Evidence for a new human CYP1A1 regulation pathway involving PPAR-alpha and 2 PPRE sites. Gastroenterology, 2004, 127(5), 1436-1445. (Pubitemid 39457770)
199. Fallone, F.; Villard, P.H.; Decome, L.; Seree, E.; Meo, M.; Chacon, C.; Durand, A.; Barra, Y.; Lacarelle, B. PPARalpha activation potentiates AhR-induced CYP1A1 expression. Toxicology, 2005, 216(2-3), 122-128. (Pubitemid 41712001)
200. Pavek, P.; Pospechova, K.; Svecova, L.; Syrova, Z.; Stejskalova, L.; Blazkova, J.; Dvorak, Z.; Blahos, J. Intestinal cell-specific vitamin D receptor (VDR)-mediated transcriptional regulation of CYP3A4 gene. Biochem. Pharmacol., 2010, 79(2), 277-287.
201. Drocourt, L.; Ourlin, J.C.; Pascussi, J.M.; Maurel, P.; Vilarem, M.J. Expression of CYP3A4, CYP2B6, and CYP2C9 is regulated by the vitamin D receptor pathway in primary human hepatocytes. J. Biol. Chem., 2002, 277(28), 25125-25132. (Pubitemid 34951818)
202. Wang, K.; Chen, S.; Xie, W.; Wan, Y.J. Retinoids induce cytochrome P450 3A4 through RXR/VDR-mediated pathway. Biochem. Pharmacol., 2008, 75(11), 2204-2213.
203. Matsubara, T.; Yoshinari, K.; Aoyama, K.; Sugawara, M.; Sekiya, Y.; Nagata, K.; Yamazoe, Y. Role of vitamin D receptor in the lithocholic acid-mediated CYP3A induction in vitro and in vivo. Drug Metab. Dispos., 2008, 36(10), 2058-2063.
204. Pascussi, J.M.; Busson-Le Coniat, M.; Maurel, P.; Vilarem, M.J. Transcriptional analysis of the orphan nuclear receptor constitutive androstane receptor (NR1I3) gene promoter: Identification of a distal glucocorticoid response element. Mol. Endocrinol., 2003, 17(1), 42-55. (Pubitemid 36132658)
205. Pascussi, J.M.; Drocourt, L.; Fabre, J.M.; Maurel, P.; Vilarem, M.J. Dexamethasone induces pregnane X receptor and retinoid X receptor- alpha expression in human hepatocytes: Synergistic increase of CYP3A4 induction by pregnane X receptor activators. Mol. Pharmacol., 2000, 58(2), 361-372. (Pubitemid 30497480)
206. Dvorak, Z.; Vrzal, R.; Ulrichova, J.; Macejova, D.; Ondkova, S.; Brtko, J. Expression, protein stability and transcriptional activity of retinoic acid receptors are affected by microtubules interfering agents and all-trans-retinoic acid in primary rat hepatocytes. Mol. Cell Endocrinol., 2007, 267(1-2), 89-96.
207. Shimada, T. Xenobiotic-metabolizing enzymes involved in activation and detoxification of carcinogenic polycyclic aromatic hydrocarbons. Drug Metab. Pharmacokinet., 2006, 21(4), 257-276.
208. Zhou, S.F.; Wang, B.; Yang, L.P.; Liu, J.P. Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2. Drug Metab. Rev., 2010, 42(2), 268-354.
209. Wojcikowski, J.; Boksa, J.; Daniel, W.A. Main contribution of the cytochrome P450 isoenzyme 1A2 (CYP1A2) to N-demethylation and 5-sulfoxidation of the phenothiazine neuroleptic chlorpromazine in human liver-A comparison with other phenothiazines. Biochem. Pharmacol., 2010, 80(8), 1252-1259.
210. Roberts, E.S.; Vaz, A.D.; Coon, M.J. Role of isozymes of rabbit microsomal cytochrome P-450 in the metabolism of retinoic acid, retinol, and retinal. Mol. Pharmacol., 1992, 41(2), 427-433.
211. Wei, C.; Caccavale, R.J.; Kehoe, J.J.; Thomas, P.E.; Iba, M.M. CYP1A2 is expressed along with CYP1A1 in the human lung. Cancer Lett., 2001, 171(1), 113-120. (Pubitemid 32727362)
212. Hakkola, J.; Pasanen, M.; Pelkonen, O.; Hukkanen, J.; Evisalmi, S.; Anttila, S.; Rane, A.; Mantyla, M.; Purkunen, R.; Saarikoski, S.; Tooming, M.; Raunio, H. Expression of CYP1B1 in human adult and fetal tissues and differential inducibility of CYP1B1 and CYP1A1 by Ah receptor ligands in human placenta and cultured cells. Carcinogenesis, 1997, 18(2), 391-397. (Pubitemid 28132434)
213. Lin, P.; Chang, H.; Ho, W.L.; Wu, M.H.; Su, J.M. Association of aryl hydrocarbon receptor and cytochrome P4501B1 expressions in human non-small cell lung cancers. Lung Cancer, 2003, 42(3), 255-261. (Pubitemid 37468537)
214. Murray, G.I.; Melvin, W.T.; Greenlee, W.F.; Burke, M.D. Regulation, function, and tissue-specific expression of cytochrome P450 CYP1B1. Annu. Rev. Pharmacol. Toxicol., 2001, 41, 297-316. (Pubitemid 32390115)
215. Swanson, H.I.; Chan, W.K.; Bradfield, C.A. DNA binding specificities and pairing rules of the Ah receptor, ARNT, and SIM proteins. J. Biol. Chem., 1995, 270(44), 26292-26302.
216. Yoshinari, K.; Yoda, N.; Toriyabe, T.; Yamazoe, Y. Constitutive androstane receptor transcriptionally activates human CYP1A1 and CYP1A2 genes through a common regulatory element in the 5'- flanking region. Biochem. Pharmacol., 2010, 79(2), 261-269.
217. Degawa, M.; Hishinuma, T.; Yoshida, H.; Hashimoto, Y. Species, sex and organ differences in induction of a cytochrome P-450 isozyme responsible for carcinogen activation: Effects of dietary hepatocarcinogenic tryptophan pyrolysate components in mice and rats. Carcinogenesis, 1987, 8(12), 1913-1918. (Pubitemid 17163954)
218. Kojima, M.; Sekimoto, M.; Degawa, M. A novel gender-related difference in the constitutive expression of hepatic cytochrome P4501A subfamily enzymes in Meishan pigs. Biochem. Pharmacol., 2008, 75(5), 1076-1082.
219. Kuil, C.W.; Brouwer, A.; van der Saag, P.T.; van der Burg, B. Interference between progesterone and dioxin signal transduction pathways. Different mechanisms are involved in repression by the progesterone receptor A and B isoforms. J. Biol. Chem., 1998, 273(15), 8829-8834. (Pubitemid 28176163)
220. Lee, S.S.; Jeong, H.G.; Yang, K.H. Effects of estradiol and progesterone on cytochrome P4501A1 expression in Hepa 1c1c7 cells. Biochem. Mol. Biol. Int., 1998, 45(4), 775-781. (Pubitemid 28393546)
221. Eugster, H.P.; Probst, M.; Wurgler, F.E.; Sengstag, C. Caffeine, estradiol, and progesterone interact with human CYP1A1 and CYP1A2. Evidence from cDNA-directed expression in Saccharomyces cerevisiae. Drug Metab. Dispos., 1993, 21(1), 43-49. (Pubitemid 23052220)
222. Matthews, J.; Wihlen, B.; Thomsen, J.; Gustafsson, J.A. Aryl hydrocarbon receptor-mediated transcription: Ligand-dependent recruitment of estrogen receptor alpha to 2,3,7,8-tetrachlorodibenzop- dioxin-responsive promoters. Mol. Cell Biol., 2005, 25(13), 5317-5328. (Pubitemid 40861696)
223. MacPherson, L.; Lo, R.; Ahmed, S.; Pansoy, A.; Matthews, J. Activation function 2 mediates dioxin-induced recruitment of estrogen receptor alpha to CYP1A1 and CYP1B1. Biochem. Biophys. Res. Commun., 2009, 385(2), 263-268.
224. Porter, W.; Wang, F.; Duan, R.; Qin, C.; Castro-Rivera, E.; Kim, K.; Safe, S. Transcriptional activation of heat shock protein 27 gene expression by 17beta-estradiol and modulation by antiestrogens and aryl hydrocarbon receptor agonists. J. Mol. Endocrinol., 2001, 26(1), 31-42. (Pubitemid 32140377)
225. Duan, R.; Porter, W.; Samudio, I.; Vyhlidal, C.; Kladde, M.; Safe, S. Transcriptional activation of c-fos protooncogene by 17betaestradiol: Mechanism of aryl hydrocarbon receptor-mediated inhibition. Mol. Endocrinol., 1999, 13(9), 1511-1521. (Pubitemid 30650592)
226. White, T.E.; Gasiewicz, T.A. The human estrogen receptor structural gene contains a DNA sequence that binds activated mouse and human Ah receptors: A possible mechanism of estrogen receptor regulation by 2,3,7,8- tetrachlorodibenzo-p-dioxin. Biochem. Biophys. Res. Commun., 1993, 193(3), 956-962. (Pubitemid 23209687)
227. Kumar, M.B.; Perdew, G.H. Nuclear receptor coactivator SRC-1 interacts with the Q-rich subdomain of the AhR and modulates its transactivation potential. Gene Expr., 1999, 8(5-6), 273-286. (Pubitemid 30637487)
228. Kumar, M.B.; Tarpey, R.W.; Perdew, G.H. Differential recruitment of coactivator RIP140 by Ah and estrogen receptors. Absence of a role for LXXLL motifs. J. Biol. Chem., 1999, 274(32), 22155-22164.
229. Angus, W.G.; Larsen, M.C.; Jefcoate, C.R. Expression of CYP1A1 and CYP1B1 depends on cell-specific factors in human breast cancer cell lines: Role of estrogen receptor status. Carcinogenesis, 1999, 20(6), 947-955. (Pubitemid 29263735)
230. Han, E.H.; Kim, H.G.; Hwang, Y.P.; Song, G.Y.; Jeong, H.G. Prostaglandin E2 induces CYP1B1 expression via ligandindependent activation of the ERalpha pathway in human breast cancer cells. Toxicol. Sci., 2010, 114(2), 204-216.
231. Monostory, K.; Kohalmy, K.; Prough, R.A.; Kobori, L.; Vereczkey, L. The effect of synthetic glucocorticoid, dexamethasone on CYP1A1 inducibility in adult rat and human hepatocytes. FEBS Lett., 2005, 579(1), 229-235. (Pubitemid 40023401)
232. Sonneveld, E.; Jonas, A.; Meijer, O.C.; Brouwer, A.; van der Burg, B. Glucocorticoid-enhanced expression of dioxin target genes through regulation of the rat aryl hydrocarbon receptor. Toxicol. Sci., 2007, 99(2), 455-469. (Pubitemid 351753063)
233. Vrzal, R.; Stejskalova, L.; Monostory, K.; Maurel, P.; Bachleda, P.; Pavek, P.; Dvorak, Z. Dexamethasone controls aryl hydrocarbon receptor (AhR)-mediated CYP1A1 and CYP1A2 expression and activity in primary cultures of human hepatocytes. Chem. Biol. Interact., 2009, 179(2-3), 288-296.
234. Dvorak, Z.; Vrzal, R.; Pavek, P.; Ulrichova, J. An evidence for regulatory cross-talk between aryl hydrocarbon receptor and glucocorticoid receptor in HepG2 cells. Physiol. Res., 2008, 57(3), 427-435.
235. Vrzal, R.; Daujat-Chavanieu, M.; Pascussi, J.M.; Ulrichova, J.; Maurel, P.; Dvorak, Z. Microtubules-interfering agents restrict aryl hydrocarbon receptor-mediated CYP1A2 induction in primary cultures of human hepatocytes via c-jun-N-terminal kinase and glucocorticoid receptor. Eur. J. Pharmacol., 2008, 581(3), 244-254.
236. Nguyen, T.A.; Hoivik, D.; Lee, J.E.; Safe, S. Interactions of nuclear receptor coactivator/corepressor proteins with the aryl hydrocarbon receptor complex. Arch. Biochem. Biophys., 1999, 367(2), 250-257. (Pubitemid 29394172)
237. Froidevaux, M.S.; Berg, P.; Seugnet, I.; Decherf, S.; Becker, N.; Sachs, L.M.; Bilesimo, P.; Nygard, M.; Pongratz, I.; Demeneix, B.A. The co-chaperone XAP2 is required for activation of hypothalamic thyrotropin-releasing hormone transcription in vivo. EMBO Rep., 2006, 7(10), 1035-1039. (Pubitemid 44480520)
238. Nilsson, C.B.; Hakansson, H. The retinoid signaling system-a target in dioxin toxicity. Crit. Rev. Toxicol., 2002, 32(3), 211-232. (Pubitemid 34615405)
239. Lu, Y.; Wang, X.; Safe, S. Interaction of 2,3,7,8- tetrachlorodibenzo-p- dioxin and retinoic acid in MCF-7 human breast cancer cells. Toxicol. Appl. Pharmacol., 1994, 127(1), 1-8. (Pubitemid 24248627)
240. Murphy, K.A.; Villano, C.M.; Dorn, R.; White, L.A. Interaction between the aryl hydrocarbon receptor and retinoic acid pathways increases matrix metalloproteinase-1 expression in keratinocytes. J. Biol. Chem., 2004, 279(24), 25284-25293. (Pubitemid 38756781)
241. Novak, J.; Benisek, M.; Pachernik, J.; Janosek, J.; Sidlova, T.; Kiviranta, H.; Verta, M.; Giesy, J.P.; Blaha, L.; Hilscherova, K. Interference of contaminated sediment extracts and environmental pollutants with retinoid signaling. Environ. Toxicol. Chem., 2007, 26(8), 1591-1599. (Pubitemid 47265499)
242. Wanner, R.; Brommer, S.; Czarnetzki, B.M.; Rosenbach, T. The differentiation-related upregulation of aryl hydrocarbon receptor transcript levels is suppressed by retinoic acid. Biochem. Biophys. Res. Commun., 1995, 209(2), 706-711.
243. Wanner, R.; Panteleyev, A.; Henz, B.M.; Rosenbach, T. Retinoic acid affects the expression rate of the differentiation-related genes aryl hydrocarbon receptor, ARNT and keratin 4 in proliferative keratinocytes only. Biochim. Biophys. Acta, 1996, 1317(2), 105-111. (Pubitemid 26388779)
244. Gambone, C.J.; Hutcheson, J.M.; Gabriel, J.L.; Beard, R.L.; Chandraratna, R.A.; Soprano, K.J.; Soprano, D.R. Unique property of some synthetic retinoids: Activation of the aryl hydrocarbon receptor pathway. Mol. Pharmacol., 2002, 61(2), 334-342. (Pubitemid 34112808)
245. Kawai, M.; Chen, J.; Cheung, C.Y.; Chang, T.K. Transcript profiling of cytochrome P450 genes in HL-60 human leukemic cells: Upregulation of CYP1B1 by all-trans-retinoic acid. Mol. Cell Biochem., 2003, 248(1-2), 57-65. (Pubitemid 36833641)
246. Rushing, S.R.; Denison, M.S. The silencing mediator of retinoic acid and thyroid hormone receptors can interact with the aryl hydrocarbon (Ah) receptor but fails to repress Ah receptor-dependent gene expression. Arch. Biochem. Biophys., 2002, 403(2), 189-201. (Pubitemid 34803195)
247. Vecchini, F.; Lenoir-Viale, M.C.; Cathelineau, C.; Magdalou, J.; Bernard, B.A.; Shroot, B. Presence of a retinoid responsive element in the promoter region of the human cytochrome P4501A1 gene. Biochem. Biophys. Res. Commun., 1994, 201(3), 1205-1212. (Pubitemid 24234218)
248. Pitarque, M.; Rodriguez-Antona, C.; Oscarson, M.; Ingelman- Sundberg, M. Transcriptional regulation of the human CYP2A6 gene. J. Pharmacol. Exp. Ther., 2005, 313(2), 814-822. (Pubitemid 40604183)
249. Meunier, V.; Bourrie, M.; Julian, B.; Marti, E.; Guillou, F.; Berger, Y.; Fabre, G. Expression and induction of CYP1A1/1A2, CYP2A6 and CYP3A4 in primary cultures of human hepatocytes: A 10-year follow-up. Xenobiotica, 2000, 30(6), 589-607. (Pubitemid 30449569)
250. Onica, T.; Nichols, K.; Larin, M.; Ng, L.; Maslen, A.; Dvorak, Z.; Pascussi, J.M.; Vilarem, M.J.; Maurel, P.; Kirby, G.M. Dexamethasone- Mediated Up-Regulation of Human CYP2A6 Involves the Glucocorticoid Receptor and Increased Binding of Hepatic Nuclear Factor 4{alpha} to the Proximal Promoter. Mol. Pharmacol., 2008, 73(2), 451-460. (Pubitemid 351159215)
251. Kojima, K.; Nagata, K.; Matsubara, T.; Yamazoe, Y. Broad but distinct role of pregnane x receptor on the expression of individual cytochrome p450s in human hepatocytes. Drug Metab. Pharmacokinet., 2007, 22(4), 276-286.
252. Itoh, M.; Nakajima, M.; Higashi, E.; Yoshida, R.; Nagata, K.; Yamazoe, Y.; Yokoi, T. Induction of human CYP2A6 is mediated by the pregnane X receptor with peroxisome proliferator-activated receptor-gamma coactivator 1alpha. J. Pharmacol. Exp. Ther., 2006, 319(2), 693-702.
253. Gervot, L.; Rochat, B.; Gautier, J.C.; Bohnenstengel, F.; Kroemer, H.; de Berardinis, V.; Martin, H.; Beaune, P.; de Waziers, I. Human CYP2B6: Expression, inducibility and catalytic activities. Pharmacogenetics, 1999, 9(3), 295-306. (Pubitemid 29376373)
254. Code, E.L.; Crespi, C.L.; Penman, B.W.; Gonzalez, F.J.; Chang, T.K.; Waxman, D.J. Human cytochrome P4502B6: Interindividual hepatic expression, substrate specificity, and role in procarcinogen activation. Drug Metab. Dispos., 1997, 25(8), 985-993. (Pubitemid 27357697)
255. Saussele, T.; Burk, O.; Blievernicht, J.K.; Klein, K.; Nussler, A.; Nussler, N.; Hengstler, J.G.; Eichelbaum, M.; Schwab, M.; Zanger, U.M. Selective induction of human hepatic cytochromes P450 2B6 and 3A4 by metamizole. Clin. Pharmacol. Ther., 2007, 82(3), 265-274. (Pubitemid 47258464)
256. Kharasch, E.D.; Mitchell, D.; Coles, R.; Blanco, R. Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir. Antimicrob. Agents Chemother., 2008, 52(5), 1663-1669. (Pubitemid 351614658)
257. Piton, A.; Rauch, C.; Langouet, S.; Guillouzo, A.; Morel, F. Involvement of pregnane X receptor in the regulation of CYP2B6 gene expression by oltipraz in human hepatocytes. Toxicol. In Vitro, 2010, 24(2), 452-459.
258. Merrell, M.D.; Jackson, J.P.; Augustine, L.M.; Fisher, C.D.; Slitt, A.L.; Maher, J.M.; Huang, W.; Moore, D.D.; Zhang, Y.; Klaassen, C.D.; Cherrington, N.J. The Nrf2 activator oltipraz also activates the constitutive androstane receptor. Drug Metab. Dispos., 2008, 36(8), 1716-1721.
259. Kocarek, T.A.; Dahn, M.S.; Cai, H.; Strom, S.C.; Mercer-Haines, N.A. Regulation of CYP2B6 and CYP3A expression by hydroxymethylglutaryl coenzyme A inhibitors in primary cultured human hepatocytes. Drug Metab. Dispos., 2002, 30(12), 1400-1405. (Pubitemid 35397045)
260. Takizawa, D.; Kakizaki, S.; Horiguchi, N.; Tojima, H.; Yamazaki, Y.; Ichikawa, T.; Sato, K.; Mori, M. Histone deacetylase inhibitors induce cytochrome P450 2B by activating nuclear receptor CAR. Drug Metab. Dispos., 2010, 38(9), 1493-1498.
261. Wang, H.; Faucette, S.; Moore, R.; Sueyoshi, T.; Negishi, M.; LeCluyse, E. Human constitutive androstane receptor mediates induction of CYP2B6 gene expression by phenytoin. J. Biol. Chem., 2004, 279(28), 29295-29301. (Pubitemid 38915806)
262. Kohalmy, K.; Tamasi, V.; Kobori, L.; Sarvary, E.; Pascussi, J.M.; Porrogi, P.; Rozman, D.; Prough, R.A.; Meyer, U.A.; Monostory, K. Dehydroepiandrosterone induces human CYP2B6 through the constitutive androstane receptor. Drug Metab. Dispos., 2007, 35(9), 1495-1501. (Pubitemid 47296041)
263. Faucette, S.R.; Zhang, T.C.; Moore, R.; Sueyoshi, T.; Omiecinski, C.J.; LeCluyse, E.L.; Negishi, M.; Wang, H. Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers. J. Pharmacol. Exp. Ther., 2007, 320(1), 72-80. (Pubitemid 46025721)
264. Casabar, R.C.; Das, P.C.; Dekrey, G.K.; Gardiner, C.S.; Cao, Y.; Rose, R.L.; Wallace, A.D. Endosulfan induces CYP2B6 and CYP3A4 by activating the pregnane X receptor. Toxicol. Appl. Pharmacol., 2010, 245(3), 335-343.
265. Goodwin, B.; Moore, L.B.; Stoltz, C.M.; McKee, D.D.; Kliewer, S.A. Regulation of the human CYP2B6 gene by the nuclear pregnane X receptor. Mol. Pharmacol., 2001, 60(3), 427-431. (Pubitemid 32781548)
266. Wang, H.; Negishi, M. Transcriptional regulation of cytochrome p450 2B genes by nuclear receptors. Curr. Drug Metab., 2003, 4(6), 515-525. (Pubitemid 37536872)
267. Chang, T.K.; Bandiera, S.M.; Chen, J. Constitutive androstane receptor and pregnane X receptor gene expression in human liver: Interindividual variability and correlation with CYP2B6 mRNA levels. Drug Metab. Dispos., 2003, 31(1), 7-10. (Pubitemid 36735251)
268. Faucette, S.R.; Sueyoshi, T.; Smith, C.M.; Negishi, M.; Lecluyse, E.L.; Wang, H. Differential regulation of hepatic CYP2B6 and CYP3A4 genes by constitutive androstane receptor but not pregnane X receptor. J. Pharmacol. Exp. Ther., 2006, 317(3), 1200-1209. (Pubitemid 43764125)
269. Swales, K.; Kakizaki, S.; Yamamoto, Y.; Inoue, K.; Kobayashi, K.; Negishi, M. Novel CAR-mediated mechanism for synergistic activation of two distinct elements within the human cytochrome P450 2B6 gene in HepG2 cells. J. Biol. Chem., 2005, 280(5), 3458-3466. (Pubitemid 40223810)
270. Jover, R.; Bort, R.; Gomez-Lechon, M.J.; Castell, J.V. Reexpression of C/EBP alpha induces CYP2B6, CYP2C9 and CYP2D6 genes in HepG2 cells. FEBS Lett., 1998, 431(2), 227-230. (Pubitemid 28334222)
271. Jover, R.; Bort, R.; Gomez-Lechon, M.J.; Castell, J.V. Cytochrome P450 regulation by hepatocyte nuclear factor 4 in human hepatocytes: A study using adenovirus-mediated antisense targeting. Hepatology, 2001, 33(3), 668-675. (Pubitemid 32185230)
272. Benet, M.; Lahoz, A.; Guzman, C.; Castell, J.V.; Jover, R. CCAAT/enhancer-binding protein {alpha} (C/EBP{alpha}) and hepatocyte nuclear factor 4{alpha} (HNF4{alpha}) synergistically cooperate with constitutive androstane receptor (CAR) to transactivate the human cytochrome P450 2B6 (CYP2B6) gene: Application to the development of a metabolically competent human hepatic cell model. J. Biol. Chem., 2010, 285(37), 28457-28471.
273. Pascual, M.; Gomez-Lechon, M.J.; Castell, J.V.; Jover, R. ATF5 is a highly abundant liver-enriched transcription factor that cooperates with constitutive androstane receptor in the transactivation of CYP2B6: Implications in hepatic stress responses. Drug Metab. Dispos., 2008, 36(6), 1063-1072. (Pubitemid 351717463)
274. Inoue, K.; Negishi, M. Nuclear receptor CAR requires early growth response 1 to activate the human cytochrome P450 2B6 gene. J. Biol. Chem., 2008, 283(16), 10425-10432.
275. Lo, R.; Burgoon, L.; Macpherson, L.; Ahmed, S.; Matthews, J. Estrogen receptor-dependent regulation of CYP2B6 in human breast cancer cells. Biochim. Biophys. Acta., 2010, 1799(5-6), 469-479.
276. Duniec-Dmuchowski, Z.; Ellis, E.; Strom, S.C.; Kocarek, T.A. Regulation of CYP3A4 and CYP2B6 expression by liver X receptor agonists. Biochem. Pharmacol., 2007, 74(10), 1535-1540. (Pubitemid 47575498)
277. Duniec-Dmuchowski, Z.; Fang, H.L.; Strom, S.C.; Ellis, E.; Runge- Morris, M.; Kocarek, T.A. Human pregnane X receptor activation and CYP3A4/CYP2B6 induction by 2,3-oxidosqualene:lanosterol cyclase inhibition. Drug Metab. Dispos., 2009, 37(4), 900-908.
278. Pascussi, J.M.; Gerbal-Chaloin, S.; Fabre, J.M.; Maurel, P.; Vilarem, M.J. Dexamethasone enhances constitutive androstane receptor expression in human hepatocytes: Consequences on cytochrome P450 gene regulation. Mol. Pharmacol., 2000, 58(6), 1441-1450.
279. Wang, H.; Faucette, S.R.; Gilbert, D.; Jolley, S.L.; Sueyoshi, T.; Negishi, M.; LeCluyse, E.L. Glucocorticoid receptor enhancement of pregnane X receptor-mediated CYP2B6 regulation in primary human hepatocytes. Drug Metab. Dispos., 2003, 31(5), 620-630. (Pubitemid 36444171)
280. Moreau, A.; Maurel, P.; Vilarem, M.J.; Pascussi, J.M. Constitutive androstane receptor-vitamin D receptor crosstalk: Consequence on CYP24 gene expression. Biochem. Biophys. Res. Commun., 2007, 360(1), 76-82. (Pubitemid 46990325)
281. Tzameli, I.; Chua, S.S.; Cheskis, B.; Moore, D.D. Complex effects of rexinoids on ligand dependent activation or inhibition of the xenobiotic receptor, CAR. Nucl. Recept., 2003, 1(1), 2.
282. Dvorak, Z.; Modriansky, M.; Pichard-Garcia, L.; Balaguer, P.; Vilarem, M.J.; Ulrichova, J.; Maurel, P.; Pascussi, J.M. Colchicine down-regulates cytochrome P450 2B6, 2C8, 2C9, and 3A4 in human hepatocytes by affecting their glucocorticoid receptormediated regulation. Mol. Pharmacol., 2003, 64(1), 160-169. (Pubitemid 36759828)
283. Gerbal-Chaloin, S.; Pascussi, J.M.; Pichard-Garcia, L.; Daujat, M.; Waechter, F.; Fabre, J.M.; Carrere, N.; Maurel, P. Induction of CYP2C genes in human hepatocytes in primary culture. Drug Metab. Dispos., 2001, 29(3), 242-251. (Pubitemid 32179522)
284. Raucy, J.L.; Mueller, L.; Duan, K.; Allen, S.W.; Strom, S.; Lasker, J.M. Expression and induction of CYP2C P450 enzymes in primary cultures of human hepatocytes. J. Pharmacol. Exp. Ther., 2002, 302(2), 475-482. (Pubitemid 34787209)
285. Belic, A.; Temesvari, M.; Kohalmy, K.; Vrzal, R.; Dvorak, Z.; Rozman, D.; Monostory, K. Investigation of the CYP2C9 induction profile in human hepatocytes by combining experimental and modelling approaches. Curr. Drug Metab., 2009, 10(10), 1066-1074.
286. Sahi, J.; Shord, S.S.; Lindley, C.; Ferguson, S.; LeCluyse, E.L. Regulation of cytochrome P450 2C9 expression in primary cultures of human hepatocytes. J. Biochem. Mol. Toxicol., 2009, 23(1), 43-58.
287. Chen, Y.; Ferguson, S.S.; Negishi, M.; Goldstein, J.A. Induction of human CYP2C9 by rifampicin, hyperforin, and phenobarbital is mediated by the pregnane X receptor. J. Pharmacol. Exp. Ther., 2004, 308(2), 495-501. (Pubitemid 38134210)
288. Ferguson, S.S.; LeCluyse, E.L.; Negishi, M.; Goldstein, J.A. Regulation of human CYP2C9 by the constitutive androstane receptor: Discovery of a new distal binding site. Mol. Pharmacol., 2002, 62(3), 737-746. (Pubitemid 36329394)
289. Ibeanu, G.C.; Goldstein, J.A. Transcriptional regulation of human CYP2C genes: Functional comparison of CYP2C9 and CYP2C18 promoter regions. Biochemistry, 1995, 34(25), 8028-8036.
290. Pavek, P.; Cerveny, L.; Svecova, L.; Brysch, M.; Libra, A.; Vrzal, R.; Nachtigal, P.; Staud, F.; Ulrichova, J.; Fendrich, Z.; Dvorak, Z. Examination of Glucocorticoid receptor alpha-mediated transcriptional regulation of P-glycoprotein, CYP3A4, and CYP2C9 genes in placental trophoblast cell lines. Placenta, 2007, 28(10), 1004-1011. (Pubitemid 47355238)
291. Chen, Y.; Kissling, G.; Negishi, M.; Goldstein, J.A. The nuclear receptors constitutive androstane receptor and pregnane X receptor cross-talk with hepatic nuclear factor 4alpha to synergistically activate the human CYP2C9 promoter. J. Pharmacol. Exp. Ther., 2005, 314(3), 1125-1133. (Pubitemid 41205977)
292. Martinez-Jimenez, C.P.; Castell, J.V.; Gomez-Lechon, M.J.; Jover, R. Transcriptional activation of CYP2C9, CYP1A1, and CYP1A2 by hepatocyte nuclear factor 4alpha requires coactivators peroxisomal proliferator activated receptor-gamma coactivator 1alpha and steroid receptor coactivator 1. Mol. Pharmacol., 2006, 70(5), 1681-1692.
293. Kawashima, S.; Kobayashi, K.; Takama, K.; Higuchi, T.; Furihata, T.; Hosokawa, M.; Chiba, K. Involvement of hepatocyte nuclear factor 4alpha in the different expression level between CYP2C9 and CYP2C19 in the human liver. Drug Metab. Dispos., 2006, 34(6), 1012-1018. (Pubitemid 43763759)
294. Rana, R.; Chen, Y.; Ferguson, S.S.; Kissling, G.E.; Surapureddi, S.; Goldstein, J.A. Hepatocyte nuclear factor 4{alpha} regulates rifampicin- mediated induction of CYP2C genes in primary cultures of human hepatocytes. Drug Metab. Dispos., 2010, 38(4), 591-599.
295. Ferguson, S.S.; Chen, Y.; LeCluyse, E.L.; Negishi, M.; Goldstein, J.A. Human CYP2C8 is transcriptionally regulated by the nuclear receptors constitutive androstane receptor, pregnane X receptor, glucocorticoid receptor, and hepatic nuclear factor 4alpha. Mol. Pharmacol., 2005, 68(3), 747-757. (Pubitemid 41206028)
296. Bort, R.; Gomez-Lechon, M.J.; Castell, J.V.; Jover, R. Role of hepatocyte nuclear factor 3 gamma in the expression of human CYP2C genes. Arch. Biochem. Biophys., 2004, 426(1), 63-72. (Pubitemid 38595130)
297. Mwinyi, J.; Nekvindova, J.; Cavaco, I.; Hofmann, Y.; Pedersen, R.S.; Landman, E.; Mkrtchian, S.; Ingelman-Sundberg, M. New insights into the regulation of CYP2C9 gene expression: The role of the transcription factor GATA-4. Drug Metab. Dispos., 2010, 38(3), 415-421.
298. Mwinyi, J.; Hofmann, Y.; Pedersen, R.S.; Nekvindova, J.; Cavaco, I.; Mkrtchian, S.; Ingelman-Sundberg, M. The transcription factor GATA-4 regulates cytochrome P4502C19 gene expression. Life Sci., 2010, 86(19-20), 699-706.
299. Surapureddi, S.; Rana, R.; Reddy, J.K.; Goldstein, J.A. Nuclear receptor coactivator 6 mediates the synergistic activation of human cytochrome P-450 2C9 by the constitutive androstane receptor and hepatic nuclear factor-4alpha. Mol. Pharmacol., 2008, 74(3), 913-923.
300. Gerbal-Chaloin, S.; Daujat, M.; Pascussi, J.M.; Pichard-Garcia, L.; Vilarem, M.J.; Maurel, P. Transcriptional regulation of CYP2C9 gene. Role of glucocorticoid receptor and constitutive androstane receptor. J. Biol. Chem., 2002, 277(1), 209-217. (Pubitemid 34952047)
301. Chen, Y.; Ferguson, S.S.; Negishi, M.; Goldstein, J.A. Identification of constitutive androstane receptor and glucocorticoid receptor binding sites in the CYP2C19 promoter. Mol. Pharmacol., 2003, 64(2), 316-324. (Pubitemid 36909995)
302. Chen, Y.; Coulter, S.; Jetten, A.M.; Goldstein, J.A. Identification of human CYP2C8 as a retinoid-related orphan nuclear receptor target gene. J. Pharmacol. Exp. Ther., 2009, 329(1), 192-201.
303. Willrich, M.A.; Hirata, M.H.; Hirata, R.D. Statin regulation of CYP3A4 and CYP3A5 expression. Pharmacogenomics, 2009, 10(6), 1017-1024.
304. Nallani, S.C.; Goodwin, B.; Buckley, A.R.; Buckley, D.J.; Desai, P.B. Differences in the induction of cytochrome P450 3A4 by taxane anticancer drugs, docetaxel and paclitaxel, assessed employing primary human hepatocytes. Cancer Chemother. Pharmacol., 2004, 54(3), 219-229. (Pubitemid 39141738)
305. Raucy, J.L. Regulation of CYP3A4 expression in human hepatocytes by pharmaceuticals and natural products. Drug Metab. Dispos., 2003, 31(5), 533-539. (Pubitemid 36444161)
306. Ruhl, R.; Sczech, R.; Landes, N.; Pfluger, P.; Kluth, D.; Schweigert, F.J. Carotenoids and their metabolites are naturally occurring activators of gene expression via the pregnane X receptor. Eur. J. Nutr., 2004, 43(6), 336-343. (Pubitemid 40064269)
307. Coumoul, X.; Diry, M.; Barouki, R. PXR-dependent induction of human CYP3A4 gene expression by organochlorine pesticides. Biochem. Pharmacol., 2002, 64(10), 1513-1519. (Pubitemid 35333379)
308. Dowless, M.S.; Barbee, J.L.; Borchert, K.M.; Bocchinfuso, W.P.; Houck, K.A. Cyclic AMP-independent activation of CYP3A4 gene expression by forskolin. Eur. J. Pharmacol., 2005, 512(1), 9-13. (Pubitemid 40462357)
309. Goodwin, B.; Redinbo, M.R.; Kliewer, S.A. Regulation of cyp3a gene transcription by the pregnane x receptor. Annu. Rev. Pharmacol. Toxicol., 2002, 42, 1-23. (Pubitemid 34160517)
310. Goodwin, B.; Hodgson, E.; Liddle, C. The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module. Mol. Pharmacol., 1999, 56(6), 1329-1339.
311. Goodwin, B.; Hodgson, E.; D'Costa, D.J.; Robertson, G.R.; Liddle, C. Transcriptional regulation of the human CYP3A4 gene by the constitutive androstane receptor. Mol. Pharmacol., 2002, 62(2), 359-365. (Pubitemid 34804117)
312. Martinez-Jimenez, C.P.; Gomez-Lechon, M.J.; Castell, J.V.; Jover, R. Transcriptional regulation of the human hepatic CYP3A4: Identification of a new distal enhancer region responsive to CCAAT/enhancer-binding protein beta isoforms (liver activating protein and liver inhibitory protein). Mol. Pharmacol., 2005, 67(6), 2088-2101. (Pubitemid 41007791)
313. Rodriguez-Antona, C.; Bort, R.; Jover, R.; Tindberg, N.; Ingelman- Sundberg, M.; Gomez-Lechon, M.J.; Castell, J.V. Transcriptional regulation of human CYP3A4 basal expression by CCAAT enhancer- binding protein alpha and hepatocyte nuclear factor-3 gamma. Mol. Pharmacol., 2003, 63(5), 1180-1189. (Pubitemid 36529936)
314. Martinez-Jimenez, C.P.; Jover, R.; Donato, M.T.; Castell, J.V.; Gomez-Lechon, M.J. Transcriptional regulation and expression of CYP3A4 in hepatocytes. Curr. Drug Metab., 2007, 8(2), 185-194. (Pubitemid 46218685)
315. Bombail, V.; Taylor, K.; Gibson, G.G.; Plant, N. Role of Sp1, C/EBP alpha, HNF3, and PXR in the basal- and xenobioticmediated regulation of the CYP3A4 gene. Drug Metab. Dispos., 2004, 32(5), 525-535. (Pubitemid 38535031)
316. Matsumura, K.; Saito, T.; Takahashi, Y.; Ozeki, T.; Kiyotani, K.; Fujieda, M.; Yamazaki, H.; Kunitoh, H.; Kamataki, T. Identification of a novel polymorphic enhancer of the human CYP3A4 gene. Mol. Pharmacol., 2004, 65(2), 326-334. (Pubitemid 38134260)
317. Tegude, H.; Schnabel, A.; Zanger, U.M.; Klein, K.; Eichelbaum, M.; Burk, O. Molecular mechanism of basal CYP3A4 regulation by hepatocyte nuclear factor 4alpha: Evidence for direct regulation in the intestine. Drug Metab. Dispos., 2007, 35(6), 946-954. (Pubitemid 46804658)
318. Bhalla, S.; Ozalp, C.; Fang, S.; Xiang, L.; Kemper, J.K. Ligandactivated pregnane X receptor interferes with HNF-4 signaling by targeting a common coactivator PGC-1alpha. Functional implications in hepatic cholesterol and glucose metabolism. J. Biol. Chem., 2004, 279(43), 45139-45147. (Pubitemid 39430929)
319. Legendre, C.; Hori, T.; Loyer, P.; Aninat, C.; Ishida, S.; Glaise, D.; Lucas-Clerc, C.; Boudjema, K.; Guguen-Guillouzo, C.; Corlu, A.; Morel, F. Drug-metabolising enzymes are down-regulated by hypoxia in differentiated human hepatoma HepaRG cells: HIF-1alpha involvement in CYP3A4 repression. Eur. J. Cancer, 2009, 45(16), 2882-2892.
320. Johnson, D.R.; Li, C.W.; Chen, L.Y.; Ghosh, J.C.; Chen, J.D. Regulation and binding of pregnane X receptor by nuclear receptor corepressor silencing mediator of retinoid and thyroid hormone receptors (SMRT). Mol. Pharmacol., 2006, 69(1), 99-108. (Pubitemid 43048897)
321. Donato, M.T.; Gomez-Lechon, M.J.; Jover, R.; Nakamura, T.; Castell, J.V. Human hepatocyte growth factor down-regulates the expression of cytochrome P450 isozymes in human hepatocytes in primary culture. J. Pharmacol. Exp. Ther., 1998, 284(2), 760-767. (Pubitemid 28086669)
322. Gnerre, C.; Blattler, S.; Kaufmann, M.R.; Looser, R.; Meyer, U.A. Regulation of CYP3A4 by the bile acid receptor FXR: Evidence for functional binding sites in the CYP3A4 gene. Pharmacogenetics, 2004, 14(10), 635-645. (Pubitemid 39411263)
323. Elizondo, G.; Medina-Diaz, I.M. Induction of CYP3A4 by 1alpha,25-dyhydroxyvitamin D3 in HepG2 cells. Life Sci., 2003, 73(2), 141-149. (Pubitemid 36555934)
324. Thompson, P.D.; Jurutka, P.W.; Whitfield, G.K.; Myskowski, S.M.; Eichhorst, K.R.; Dominguez, C.E.; Haussler, C.A.; Haussler, M.R. Liganded VDR induces CYP3A4 in small intestinal and colon cancer cells via DR3 and ER6 vitamin D responsive elements. Biochem. Biophys. Res. Commun., 2002, 299(5), 730-738. (Pubitemid 36034548)
325. Yasunami, Y.; Hara, H.; Iwamura, T.; Kataoka, T.; Adachi, T. Cjun N-terminal kinase modulates 1,25-dihydroxyvitamin D3- induced cytochrome P450 3A4 gene expression. Drug Metab. Dispos., 2004, 32(7), 685-688. (Pubitemid 38821868)
326. Ourlin, J.C.; Lasserre, F.; Pineau, T.; Fabre, J.M.; Sa-Cunha, A.; Maurel, P.; Vilarem, M.J.; Pascussi, J.M. The small heterodimer partner interacts with the pregnane X receptor and represses its transcriptional activity. Mol. Endocrinol., 2003, 17(9), 1693-1703. (Pubitemid 37074859)
327. Pascussi, J.M.; Drocourt, L.; Gerbal-Chaloin, S.; Fabre, J.M.; Maurel, P.; Vilarem, M.J. Dual effect of dexamethasone on CYP3A4 gene expression in human hepatocytes. Sequential role of glucocorticoid receptor and pregnane X receptor. Eur. J. Biochem., 2001, 268(24), 6346-6358.
328. El-Sankary, W.; Plant, N.J.; Gibson, G.G.; Moore, D.J. Regulation of the CYP3A4 gene by hydrocortisone and xenobiotics: Role of the glucocorticoid and pregnane X receptors. Drug Metab. Dispos., 2000, 28(5), 493-496. (Pubitemid 30238506)
329. El-Sankary, W.; Bombail, V.; Gibson, G.G.; Plant, N. Glucocorticoid- mediated induction of CYP3A4 is decreased by disruption of a protein: DNA interaction distinct from the pregnane X receptor response element. Drug Metab. Dispos., 2002, 30(9), 1029-1034.
330. Auerbach, S.S.; Dekeyser, J.G.; Stoner, M.A.; Omiecinski, C.J. CAR2 displays unique ligand binding and RXRalpha heterodimerization characteristics. Drug Metab. Dispos., 2007, 35(3), 428-439. (Pubitemid 46333906)
331. Noreault, T.L.; Kostrubsky, V.E.; Wood, S.G.; Nichols, R.C.; Strom, S.C.; Trask, H.W.; Wrighton, S.A.; Evans, R.M.; Jacobs, J.M.; Sinclair, P.R.; Sinclair, J.F. Arsenite decreases CYP3A4 and RXRalpha in primary human hepatocytes. Drug Metab. Dispos., 2005, 33(7), 993-1003. (Pubitemid 41002782)
332. Assenat, E.; Gerbal-Chaloin, S.; Larrey, D.; Saric, J.; Fabre, J.M.; Maurel, P.; Vilarem, M.J.; Pascussi, J.M. Interleukin 1beta inhibits CAR-induced expression of hepatic genes involved in drug and bilirubin clearance. Hepatology, 2004, 40(4), 951-960. (Pubitemid 39288129)
333. Duret, C.; Daujat-Chavanieu, M.; Pascussi, J.M.; Pichard-Garcia, L.; Balaguer, P.; Fabre, J.M.; Vilarem, M.J.; Maurel, P.; Gerbal- Chaloin, S. Ketoconazole and miconazole are antagonists of the human glucocorticoid receptor: Consequences on the expression and function of the constitutive androstane receptor and the pregnane X receptor. Mol. Pharmacol., 2006, 70(1), 329-339.
334. Wang, K.; Mendy, A.J.; Dai, G.; Luo, H.R.; He, L.; Wan, Y.J. Retinoids activate the RXR/SXR-mediated pathway and induce the endogenous CYP3A4 activity in Huh7 human hepatoma cells. Toxicol. Sci., 2006, 92(1), 51-60. (Pubitemid 43985789)
335. Chen, S.; Wang, K.; Wan, Y.J. Retinoids activate RXR/CARmediated pathway and induce CYP3A. Biochem. Pharmacol., 2010, 79(2), 270-276.
336. Istrate, M.A.; Nussler, A.K.; Eichelbaum, M.; Burk, O. Regulation of CYP3A4 by pregnane X receptor: The role of nuclear receptors competing for response element binding. Biochem. Biophys. Res. Commun., 2010, 393(4), 688-693.
337. Raner, G.M.; Vaz, A.D.; Coon, M.J. Metabolism of all-trans, 9-cis, and 13-cis isomers of retinal by purified isozymes of microsomal cytochrome P450 and mechanism-based inhibition of retinoid oxidation by citral. Mol. Pharmacol., 1996, 49(3), 515-522. (Pubitemid 26087819)
338. Thatcher, J.E.; Zelter, A.; Isoherranen, N. The relative importance of CYP26A1 in hepatic clearance of all-trans retinoic acid. Biochem. Pharmacol., 2010, 80(6), 903-912.
339. Osanai, M.; Sawada, N.; Lee, G.H. Oncogenic and cell survival properties of the retinoic acid metabolizing enzyme, CYP26A1. Oncogene, 2010, 29(8), 1135-1144.
340. Osanai, M.; Petkovich, M. Expression of the retinoic acidmetabolizing enzyme CYP26A1 limits programmed cell death. Mol. Pharmacol., 2005, 67(5), 1808-1817. (Pubitemid 40594182)
341. Taimi, M.; Helvig, C.; Wisniewski, J.; Ramshaw, H.; White, J.; Amad, M.; Korczak, B.; Petkovich, M. A novel human cytochrome P450, CYP26C1, involved in metabolism of 9-cis and all-trans isomers of retinoic acid. J. Biol. Chem., 2004, 279(1), 77-85. (Pubitemid 38044801)
342. Spoorendonk, K.M.; Peterson-Maduro, J.; Renn, J.; Trowe, T.; Kranenbarg, S.; Winkler, C.; Schulte-Merker, S. Retinoic acid and Cyp26b1 are critical regulators of osteogenesis in the axial skeleton. Development, 2008, 135(22), 3765-3774.
343. Kizaki, M.; Ueno, H.; Yamazoe, Y.; Shimada, M.; Takayama, N.; Muto, A.; Matsushita, H.; Nakajima, H.; Morikawa, M.; Koeffler, H.P.; Ikeda, Y. Mechanisms of retinoid resistance in leukemic cells: Possible role of cytochrome P450 and P-glycoprotein. Blood, 1996, 87(2), 725-733. (Pubitemid 26030329)
344. Gallagher, R.E. Retinoic acid resistance in acute promyelocytic leukemia. Leukemia, 2002, 16(10), 1940-1958. (Pubitemid 35203437)
345. White, J.A.; Beckett-Jones, B.; Guo, Y.D.; Dilworth, F.J.; Bonasoro, J.; Jones, G.; Petkovich, M. cDNA cloning of human retinoic acid-metabolizing enzyme (hP450RAI) identifies a novel family of cytochromes P450. J. Biol. Chem., 1997, 272(30), 18538-18541. (Pubitemid 27318190)
346. Ray, W.J.; Bain, G.; Yao, M.; Gottlieb, D.I. CYP26, a novel mammalian cytochrome P450, is induced by retinoic acid and defines a new family. J. Biol. Chem., 1997, 272(30), 18702-18708. (Pubitemid 27318214)
347. Pavez Lorie, E.; Li, H.; Vahlquist, A.; Torma, H. The involvement of cytochrome p450 (CYP) 26 in the retinoic acid metabolism of human epidermal keratinocytes. Biochim. Biophys. Acta, 2009, 1791(3), 220-228.
348. Yamanaka, H.; Nakajima, M.; Katoh, M.; Yokoi, T. Glucuronidation of thyroxine in human liver, jejunum, and kidney microsomes. Drug Metab. Dispos., 2007, 35(9), 1642-1648. (Pubitemid 47296059)
349. Visser, T.J. Pathways of thyroid hormone metabolism. Acta Med. Austriaca, 1996, 23(1-2), 10-16. (Pubitemid 126443903)
350. Visser, T.J.; van Buuren, J.C.; Rutgers, M.; Eelkman Rooda, S.J.; de Herder, W.W. The role of sulfation in thyroid hormone metabolism. Trends Endocrinol. Metab., 1990, 1(4), 211-218. (Pubitemid 20133829)